https://trial.medpath.com/news/3f45df69edcc3bcd/medical-imaging-s-climate-impact-unnecessary-scans-contribute-significantly-to-carbon-emissions 2025-04-18T17:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/e4a05f05bad4a1e7/rising-pancreatic-cancer-rates-in-young-adults-likely-due-to-improved-detection-not-increased-disease-burden 2025-04-18T17:59:43+00:00 hourly 0.9 https://trial.medpath.com/news/3595c8583daeb8ae/breakthrough-diagnostic-tools-for-early-fatty-liver-disease-detection-ai-and-blood-tests-show-promise 2025-04-18T17:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/529048daeb6390de/er-visits-for-psychedelics-linked-to-higher-mortality-and-schizophrenia-risk-studies-find 2025-04-18T17:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/ee044be17b8d5715/ultra-rapid-genetic-test-revolutionizes-brain-cancer-surgery-with-real-time-tumor-detection 2025-04-18T17:58:14+00:00 hourly 0.9 https://trial.medpath.com/news/db9ae7c4dfdd42e6/studies-reveal-concerning-trends-in-prostate-cancer-treatment-overtreatment-rising-despite-serious-long-term-risks 2025-04-18T17:57:28+00:00 hourly 0.9 https://trial.medpath.com/news/d298e028cff68630/first-u-s-case-of-more-virulent-mpox-strain-detected-in-california-traveler 2025-04-18T17:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/f0f629e737a28a84/mental-health-crisis-deepens-anxiety-and-depression-rates-surge-among-americans-particularly-youth 2025-04-18T17:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/a04cb95a4a1ffd7f/mindfulness-and-cbt-significantly-reduce-chronic-low-back-pain-and-opioid-use-in-landmark-clinical-trial 2025-04-18T17:55:38+00:00 hourly 0.9 https://trial.medpath.com/news/1997bef441693ce5/responsive-parenting-and-digital-support-significantly-reduce-childhood-obesity-risk-studies-show 2025-04-18T17:55:09+00:00 hourly 0.9 https://trial.medpath.com/news/41d8ca34f507ce9f/autism-diagnoses-surge-175-in-the-u-s-over-past-decade-study-reveals 2025-04-18T17:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/f8074bc0106ae687/hormonal-influences-on-asthma-risk-new-studies-reveal-gender-specific-patterns 2025-04-18T17:54:18+00:00 hourly 0.9 https://trial.medpath.com/news/634c4357dc35ab6e/weekend-warrior-exercise-pattern-offers-comparable-brain-health-benefits-to-regular-activity 2025-04-18T17:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/fa5a36e87dd4f135/gut-microbiome-changes-linked-to-cognitive-decline-and-dementia-in-parkinson-s-disease 2025-04-18T17:53:21+00:00 hourly 0.9 https://trial.medpath.com/news/6f36432d22a56e32/blue-cross-blue-shield-of-massachusetts-to-end-coverage-for-weight-loss-glp-1-drugs-in-2026 2025-04-18T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/8434a94b25aeefc1/australia-approves-ifinwil-eflornithine-for-high-risk-neuroblastoma-treatment 2025-04-18T11:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/48834400b96ccb76/fda-grants-qidp-status-to-venus-remedies-novel-antibiotic-vrp-034-for-bloodstream-infections 2025-04-18T08:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/6aa9cb7f13693af6/velavigo-secures-440m-licensing-deal-for-first-in-class-bispecific-antibody-vbs-102 2025-04-18T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/f413deba34a23fb5/chugai-s-vabysmo-becomes-first-approved-treatment-for-angioid-streaks-in-japan 2025-04-18T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/6348122228984ab9/fda-clears-ind-for-nurix-and-gilead-s-novel-irak4-degrader-gs-6791-nx-0479-for-inflammatory-conditions 2025-04-18T05:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/39ea328c3a84d885/university-of-glasgow-and-mydna-partner-to-advance-pharmacogenomics-integration-in-nhs-healthcare 2025-04-18T05:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/85eb1670050d9bd4/precision-neuroscience-secures-fda-clearance-for-layer-7-cortical-interface-advancing-bci-technology 2025-04-18T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/2280804c544310a0/hikma-acquires-fda-approved-generic-trametinib-anda-securing-180-day-market-exclusivity 2025-04-18T05:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/b4d5cafc14c8f029/baypine-acquires-cenexel-clinical-research-aims-to-transform-clinical-trial-operations 2025-04-18T05:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/6402ba661cb310cf/eli-lilly-s-oral-glp-1-orforglipron-shows-promising-phase-3-results-for-weight-management 2025-04-18T03:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/2aa3cd8e2fa54479/promising-therapeutic-advances-for-rare-lymphomas-pi3k-inhibitors-ezh2-inhibitors-and-immunotherapy-show-clinical-potential 2025-04-18T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/942873a3a6978875/endevica-bio-initiates-phase-2-trial-of-tcmcb07-for-cancer-cachexia-in-metastatic-colorectal-cancer-patients 2025-04-18T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/19f2a7f4b5fb75c1/elraglusib-shows-promise-for-advanced-salivary-gland-carcinoma-in-upcoming-aacr-presentation 2025-04-18T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/5f142aa123ad3bf4/balancing-efficacy-and-cost-sustainability-in-modern-cll-treatment-insights-from-dr-pierluigi-porcu 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4652d8e56ac79349/astrazeneca-and-qure-ai-reach-5-million-ai-powered-chest-x-rays-for-lung-cancer-detection-across-20-countries 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/763ba6633683474c/sanofi-initiates-phase-2-trial-of-sar441566-for-moderate-to-severe-ulcerative-colitis 2025-04-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/16ded4f90126a49c/genedx-acquires-fabric-genomics-for-up-to-51-million-to-expand-global-genomic-diagnostics 2025-04-17T23:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/4c57aeb08480fb2b/ai-in-healthcare-standardization-and-collaboration-key-to-future-success-experts-say 2025-04-17T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/c8625b896bd67776/who-member-states-reach-historic-draft-pandemic-agreement-after-three-years-of-negotiations 2025-04-17T22:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/7a4eee935352c0a1/cdc-advisory-panel-recommends-expanded-rsv-vaccination-for-adults-50-59-with-high-risk-conditions 2025-04-17T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/5708e7c4836c90b4/avita-medical-reports-67-revenue-growth-in-q1-2025-expands-product-portfolio 2025-04-17T20:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/4a1f38579e13c653/brisk-walking-significantly-reduces-risk-of-heart-rhythm-disorders-new-study-finds 2025-04-17T20:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/7c0fb5e8e377219b/new-studies-reveal-menopause-often-begins-earlier-than-most-women-expect 2025-04-17T20:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/4f5b3a55de37ce5b/dr-mehmet-oz-confirmed-as-head-of-centers-for-medicare-medicaid-services 2025-04-17T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/782558768e69c0f3/modern-approaches-to-joint-replacement-recovery-faster-healing-less-pain 2025-04-17T20:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/26a6ec10c9d5890f/glp-1-drug-use-surges-among-type-1-diabetes-patients-despite-safety-concerns 2025-04-17T20:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/7e716a42374ada45/smartwatch-innovation-new-heart-rate-to-step-ratio-emerges-as-superior-health-indicator 2025-04-17T20:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/c5d306cc76d1b793/trump-nominates-susan-monarez-as-permanent-cdc-director-after-weldon-withdrawal 2025-04-17T20:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/1d31ef2cf2b65cb3/global-surge-in-early-onset-colorectal-cancer-demands-urgent-attention 2025-04-17T20:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/2325246f0dc6cd26/novel-screening-methods-show-promise-for-early-detection-of-cognitive-decline 2025-04-17T20:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/1ca2044b15ee5480/racial-disparities-in-ca-125-testing-may-delay-ovarian-cancer-treatment-for-black-and-native-american-women 2025-04-17T20:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/d0565b0c7c4fee23/fda-launches-operation-stork-speed-to-modernize-infant-formula-safety-and-nutrition-standards 2025-04-17T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/85aa7d6bb51514bb/measles-outbreak-spreads-across-multiple-states-with-two-fatalities-reported 2025-04-17T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/2d6c978adaf18cfc/fda-issues-warning-on-rising-nitrous-oxide-misuse-injuries-as-recreational-products-flood-market 2025-04-17T20:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/8ade3f8036c0f48a/hhs-terminates-funding-for-geovax-s-next-generation-covid-19-vaccine-amid-ongoing-clinical-trials 2025-04-17T20:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/fb8442ce2ea2f446/cannabis-use-during-pregnancy-linked-to-tripled-risk-of-behavioral-disorders-in-children 2025-04-17T20:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/e2a6d68f736bbc2a/ai-model-successfully-predicts-cognitive-decline-in-menopausal-women 2025-04-17T20:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/5b5d8e3239d64e18/anti-inflammatory-drugs-and-infection-control-may-reduce-dementia-risk-studies-suggest 2025-04-17T20:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/4d9b80e463c0f4d5/utah-becomes-first-state-to-ban-fluoride-in-public-water-systems 2025-04-17T20:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/0e50e7624a8f60c7/young-smokers-face-double-the-risk-of-unexplained-strokes-study-reveals 2025-04-17T20:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/dc139a98d5e3bd5e/environmental-pollutants-significantly-increase-childhood-asthma-risk-new-studies-reveal 2025-04-17T20:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/e5ad1917d239f24e/measles-outbreak-in-west-texas-escalates-to-58-cases-amid-low-vaccination-rates 2025-04-17T20:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/7e591d2fed59b51b/antidepressants-linked-to-increased-risk-of-sudden-cardiac-death-danish-study-reveals 2025-04-17T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/53e384a49576535f/hormonal-contraceptives-and-hrt-linked-to-increased-cardiovascular-risks-in-women 2025-04-17T20:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/a4066011218bb57b/wildfire-smoke-exposure-linked-to-prolonged-cardiovascular-and-respiratory-health-risks 2025-04-17T20:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/6480b9b2980fcd0a/roche-adjusts-tominersen-dosing-in-generation-hd2-trial-for-huntington-s-disease 2025-04-17T19:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/45a4fc3c18aed491/pregnancy-complications-linked-to-increased-heart-disease-risk-in-women-and-their-sisters 2025-04-17T19:47:14+00:00 hourly 0.9 https://trial.medpath.com/news/5e1ae33a1bb5ae8a/federal-judge-orders-cdc-and-fda-to-restore-public-health-websites-removed-under-trump-administration 2025-04-17T19:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/f96e56e208b0a746/h5n1-bird-flu-may-spread-through-airborne-transmission-czech-study-reveals 2025-04-17T19:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/31312ba0e392fe33/low-ldl-cholesterol-levels-associated-with-reduced-dementia-and-alzheimer-s-risk 2025-04-17T19:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/222d4f661714d60a/covid-19-continues-to-pose-greater-health-threat-than-flu-and-rsv-study-finds 2025-04-17T19:45:55+00:00 hourly 0.9 https://trial.medpath.com/news/592eab4ff7a2f3bc/bariatric-surgery-in-adolescents-shows-superior-long-term-health-benefits-compared-to-adults 2025-04-17T19:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/d9c42901f7b7fec0/alarming-gap-in-dementia-diagnosis-awareness-reveals-healthcare-disparities 2025-04-17T19:43:16+00:00 hourly 0.9 https://trial.medpath.com/news/7c3ce6da290c1234/adhd-persists-in-adults-with-autism-at-rates-similar-to-childhood-study-finds 2025-04-17T19:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/3c40a2fcf86b8570/ketamine-use-surges-40-in-u-s-as-medical-authorities-call-for-stricter-controls 2025-04-17T19:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/4b83cc41f952928d/menthol-cigarette-bans-drive-smokers-toward-cessation-therapies-rather-than-alternative-tobacco-products 2025-04-17T19:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/a79c48c7ffa831c0/frequent-antibiotic-use-in-early-childhood-linked-to-higher-asthma-and-allergy-risk 2025-04-17T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/26829cc75c79baa5/fda-unveils-new-front-of-package-food-labels-to-combat-chronic-disease-epidemic 2025-04-17T19:41:27+00:00 hourly 0.9 https://trial.medpath.com/news/f9296b424dade871/poor-sleep-quality-significantly-impacts-workplace-productivity-new-research-reveals 2025-04-17T19:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/37bb58a97ef533aa/exercise-significantly-reduces-cancer-mortality-risk-new-studies-confirm 2025-04-17T19:39:45+00:00 hourly 0.9 https://trial.medpath.com/news/4b38f9d81a776812/hsv-1-infection-linked-to-80-increased-alzheimer-s-risk-in-large-scale-claims-analysis 2025-04-17T19:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/3724025bfeb8bfd1/morning-coffee-consumption-linked-to-reduced-cardiovascular-death-risk-and-healthy-aging-in-women 2025-04-17T19:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/b4fba81c18e0fba2/bilingualism-boosts-cognitive-function-in-children-with-autism-new-research-finds 2025-04-17T19:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/0d31760918ef44a4/early-physical-therapy-within-two-months-critical-for-concussion-recovery-clinical-trial-reveals 2025-04-17T19:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/a042815a636d5e03/bird-flu-outbreak-linked-to-raw-pet-foods-prompts-multiple-recalls-across-us 2025-04-17T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/f6fdf6b5cefc8b35/ai-advances-in-breast-cancer-detection-new-technologies-show-promise-for-earlier-diagnosis 2025-04-17T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/9cc7f4356f6ddafa/dance-therapy-shows-promising-results-for-parkinson-s-and-alzheimer-s-patients 2025-04-17T19:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/9fbd6ad7deff0b08/norovirus-outbreaks-on-cruise-ships-intensify-one-death-reported-amid-rising-cases 2025-04-17T19:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/dd418a81b1367ef8/cdc-confirms-concerning-mutations-in-first-severe-u-s-bird-flu-case 2025-04-17T19:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/903a44366ca90e20/team-sports-enhance-cognitive-development-and-academic-success-in-children-studies-show 2025-04-17T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/5180108153fcbc66/air-pollution-during-pregnancy-linked-to-severe-neonatal-health-risks-and-brain-development-issues 2025-04-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/56c089106e551db8/omega-3-fatty-acids-show-promise-in-slowing-prostate-cancer-progression 2025-04-17T19:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/d62a82c7410ec93f/u-s-life-expectancy-rebounds-as-overdose-deaths-decline-for-first-time-in-a-decade 2025-04-17T19:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/4d52aa31bf7353d3/fda-proposes-historic-nicotine-reduction-in-tobacco-products-to-combat-addiction 2025-04-17T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/ed8cf475fbd7c1a0/pediatric-flu-deaths-reach-highest-level-since-2009-as-vaccination-rates-decline 2025-04-17T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/133176949f5e780b/study-reveals-effective-strategies-for-young-adults-quitting-vaping 2025-04-17T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/813347a4a6aab4c1/hpv-self-testing-proves-effective-for-cervical-cancer-screening-new-study-confirms 2025-04-17T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/2da46b6a7a7560f4/malaria-suspected-in-deadly-congo-outbreak-as-laboratory-tests-show-positive-results 2025-04-17T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/4d1890c93250fb05/dual-use-of-cigarettes-and-e-cigarettes-undermines-smoking-cessation-and-increases-health-risks 2025-04-17T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/6d338f4d9af4e1e8/physical-fitness-linked-to-better-cognitive-health-in-older-adults-studies-show 2025-04-17T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/793ffe04c09865eb/salmonella-outbreak-linked-to-mexican-cucumbers-expands-to-100-cases-across-23-states 2025-04-17T19:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/5f3bd3d044cea66b/socioeconomic-factors-and-parental-smoking-linked-to-worse-ms-outcomes-in-children 2025-04-17T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/640532c9b919a6e0/preterm-birth-linked-to-lifelong-socioeconomic-and-health-disadvantages-studies-reveal 2025-04-17T19:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/3f01b1a5c8a30d5a/wildfire-smoke-exposure-linked-to-increased-dementia-and-mental-health-risks-studies-find 2025-04-17T19:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/52ffa53639609554/e-coli-contamination-prompts-massive-recall-of-167000-pounds-of-ground-beef 2025-04-17T19:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/8170558b38e60970/thermo-fisher-scientific-launches-first-us-cell-therapy-collaboration-center-in-california 2025-04-17T19:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/3eb979d4a1e02c44/alcohol-related-deaths-and-cancer-fatalities-surge-in-u-s-over-past-two-decades 2025-04-17T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/f971231ddf84fc92/global-obesity-crisis-accelerating-80-of-americans-projected-to-be-overweight-or-obese-by-2050 2025-04-17T19:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/2c6f4d1af20e0844/excessive-sedentary-time-linked-to-increased-cardiovascular-risk-even-in-active-individuals 2025-04-17T19:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/d55150026f646ad1/canadian-teen-s-critical-bird-flu-case-raises-alarm-as-h5n1-infections-spread 2025-04-17T19:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/60b06a2f1551376a/adequate-sleep-significantly-reduces-hypertension-risk-in-adolescents-new-research-confirms 2025-04-17T19:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/935e6c62fd20a5db/obesity-related-cancer-deaths-more-than-triple-in-u-s-over-two-decades 2025-04-17T19:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/b0bcbdd75d271178/study-confirms-immediate-cpr-saves-lives-regardless-of-provider-training 2025-04-17T19:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/cbdbcfa560ad0da0/ai-powered-analysis-reveals-long-covid-affects-nearly-23-of-americans-higher-than-previous-estimates 2025-04-17T19:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/18c5a7ba538da9ad/sleep-disruptions-emerge-as-critical-early-indicators-of-alzheimer-s-disease-risk 2025-04-17T19:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/dff8926ad21edb2e/maternal-vitamin-d-levels-during-early-pregnancy-significantly-impact-infant-health-outcomes 2025-04-17T19:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/50ccf7c204ee19cd/whooping-cough-cases-surge-sixfold-in-the-u-s-reaching-highest-levels-since-2014 2025-04-17T19:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/292ff872e40160dc/h5n1-bird-flu-detected-in-u-s-pig-for-first-time-raising-transmission-concerns 2025-04-17T19:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/e4c1c22d94c9a3c0/health-insurance-gaps-lead-to-later-cancer-diagnoses-among-black-and-hispanic-americans 2025-04-17T19:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/a2a91b33f8b7f6c3/concussions-in-hockey-players-linked-to-doubled-risk-of-depression-and-tripled-risk-of-burnout 2025-04-17T19:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/03a9f43269232414/glp-1-medications-reshape-obesity-treatment-landscape-as-bariatric-surgeries-decline-25 2025-04-17T19:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/336541e1f44a8f18/cdc-reports-second-missouri-bird-flu-case-without-animal-exposure-as-u-s-total-reaches-67 2025-04-17T19:02:21+00:00 hourly 0.9 https://trial.medpath.com/news/800c2ecc88d0694e/expanded-glp-1-drug-access-could-save-42000-lives-and-billions-in-healthcare-costs-annually 2025-04-17T19:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/be920401d102a3f7/infant-mortality-rises-in-states-with-abortion-bans-new-jama-studies-reveal 2025-04-17T19:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/8ecc0b6683d39832/election-related-stress-reaches-critical-levels-among-americans-apa-survey-reveals 2025-04-17T19:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/9bda2f322a993a5a/taylor-farms-recalls-onions-linked-to-deadly-e-coli-outbreak-in-mcdonald-s-quarter-pounders 2025-04-17T19:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/833b3a543aacf9b0/pfas-forever-chemicals-contaminate-drinking-water-for-75-95-million-americans-usgs-study-reveals 2025-04-17T19:00:59+00:00 hourly 0.9 https://trial.medpath.com/news/553c73e750e34337/physical-activity-in-childhood-linked-to-better-mental-health-and-cognitive-function-in-adolescence 2025-04-17T19:00:53+00:00 hourly 0.9 https://trial.medpath.com/news/6539e5d121949991/fda-grants-510-k-clearance-to-bvi-medical-s-novel-laser-system-for-glaucoma-treatment 2025-04-17T18:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/e81c4cd9a3ae4aff/fda-approves-25-first-time-generic-drugs-in-first-half-of-2025-expanding-access-to-critical-therapies 2025-04-17T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/ba78e357041330b8/probiogen-s-glymaxx-technology-powers-commercially-available-her2-biliary-cancer-treatment 2025-04-17T17:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/715e5d8dfff9b133/galmed-s-aramchol-shows-promising-results-in-enhancing-regorafenib-s-efficacy-against-gi-cancers 2025-04-17T17:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/45f91ccf0ec09bde/sol-gel-and-mayne-pharma-announce-16-million-deal-for-epsolay-and-twyneo-rights-in-the-u-s 2025-04-17T17:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/55749976615acb74/trump-s-executive-order-delays-medicare-drug-price-negotiations-sparking-industry-and-policy-debate 2025-04-17T15:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/e86550dc1b9afb38/ligand-s-pelthos-therapeutics-to-merge-with-channel-therapeutics-in-50m-deal-focused-on-molluscum-treatment 2025-04-17T15:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/0a1623ade4ff7d09/channel-therapeutics-and-pelthos-therapeutics-merge-to-accelerate-zelsuvmi-launch-for-molluscum-contagiosum 2025-04-17T15:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/b5541a473e39eb37/dasatinib-plus-car-t-cell-therapy-achieves-85-complete-molecular-remission-in-newly-diagnosed-ph-all 2025-04-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/895327595e52d01e/alembic-pharmaceuticals-secures-usfda-approvals-for-carbamazepine-and-amlodipine-atorvastatin-generics 2025-04-17T14:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc091b17d5186e69/trodelvy-keytruda-combination-shows-promising-results-in-first-line-treatment-for-triple-negative-breast-cancer 2025-04-17T14:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/41e49d79f888412e/caliway-s-cbl-514-shows-promising-phase-2-results-for-dercum-s-disease-advancing-to-phase-2b-trial 2025-04-17T14:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/a1e3606ecf82d7c2/india-bans-35-unapproved-fixed-dose-combination-drugs-over-safety-concerns 2025-04-17T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/496a6c3a6488c1ec/3d-pathology-technology-reclassifies-67-of-her2-null-breast-cancer-cases-as-her2-expressing 2025-04-17T12:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/307cf475d857cdfe/diabetes-drug-metformin-shows-promise-in-preventing-acute-myeloid-leukemia 2025-04-17T11:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/3179a4199a9ca9ea/solo-pace-receives-fda-clearance-for-novel-tavr-pacing-system-with-first-successful-human-procedures 2025-04-17T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/d50cee92433fb566/fda-clears-medline-s-reflex-hybrid-nitinol-implants-for-foot-and-ankle-surgery 2025-04-17T09:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/041d4cf7dea0d253/glenmark-to-launch-generic-adderall-in-may-2025-amid-ongoing-shortage 2025-04-17T09:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/fd048c664ff56abb/design-therapeutics-appoints-dr-chris-storgard-as-chief-medical-officer-to-advance-genetac-r-pipeline 2025-04-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/35292f31bcefd262/eli-lilly-commits-1-3-billion-to-verve-therapeutics-cardiovascular-gene-therapy-platform 2025-04-17T06:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/3ee102a82a199ed2/porton-advanced-accelerates-development-of-innovative-cell-therapies-for-solid-tumors-with-key-partnerships 2025-04-17T06:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/f50a6fdc40064e2a/iga-nephropathy-pipeline-shows-robust-growth-with-30-therapies-in-development 2025-04-17T06:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/bba7c5e915cecd24/sabin-launches-u-s-phase-2-trial-for-marburg-vaccine-amid-rising-global-outbreaks 2025-04-17T06:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/fcf1fc90873a4b77/podo-therapeutics-advances-cancer-precision-medicine-with-novel-organoid-immune-cell-co-culture-platform 2025-04-17T06:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/1e7236c1df57f626/bayer-secures-fda-approval-for-nubeqa-in-metastatic-prostate-cancer-targeting-eur3-billion-peak-sales 2025-04-17T05:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/df005810fd97d281/yunu-secures-oversubscribed-funding-to-transform-clinical-trial-imaging-workflows 2025-04-17T05:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/5b8da55bb9e1d9c3/sonrai-and-paige-partner-to-accelerate-precision-medicine-r-d-with-advanced-ai-capabilities 2025-04-17T02:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/8ba4746adaf387e3/global-regulatory-landscape-for-psoriasis-and-pompe-disease-treatments-evolving-in-2025 2025-04-17T02:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/011c27e00807a6a0/sebiotic-r-probiotic-shows-96-efficacy-in-treating-drug-induced-constipation-in-clinical-trial 2025-04-17T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/28b744c3eb651255/biosidus-reports-positive-phase-iii-interim-results-for-agalsidase-beta-biosimilar-in-fabry-disease 2025-04-17T00:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/60fdfd1bf764e433/verrica-pharmaceuticals-reports-record-growth-in-ycanth-r-dispensed-units-for-molluscum-contagiosum-treatment 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebe5a1db57f7dcbd/synaptixbio-selects-antisense-oligonucleotide-candidate-for-rare-disease-h-abc-clinical-trials 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae69c9373d4934a7/amt-medical-secures-25m-series-b-to-transform-coronary-bypass-surgery-with-minimally-invasive-technology 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14a9a7f11bc0b89d/mark-cuban-s-cost-plus-drug-company-partners-with-morris-dickson-to-address-injectable-medication-shortages 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0fedd16ec6688736/fda-rehires-key-pharma-user-fee-negotiators-after-mass-layoffs-threaten-drug-review-process 2025-04-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/57af7f8c44740f5f/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-asset-purchase-deals-from-2019-2025 2025-04-16T23:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/a5c5b6488ee27633/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-to-phase-1-trial-for-rheumatoid-arthritis-in-europe 2025-04-16T23:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/1b4737a77e13f732/tlx101-shows-promising-survival-benefits-in-recurrent-high-grade-glioma-patients 2025-04-16T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/bf9c41998794d28a/ingenu-cro-launches-pioneering-clinical-trials-for-idiopathic-hypersomnia-and-narcolepsy 2025-04-16T20:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/b503427be4cf919e/redhill-s-opaganib-shows-promise-for-weight-loss-and-diabetes-potentially-disrupting-100b-market 2025-04-16T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/8766066ccc805e5e/fda-expands-osilodrostat-isturisa-indication-for-broader-cushing-s-syndrome-treatment 2025-04-16T20:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/fff3d7ddda2a1f6f/fda-grants-orphan-drug-designation-to-scilex-s-liquid-colchicine-for-pericarditis-treatment 2025-04-16T20:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/8796d8feb333f2f5/recursion-licenses-healthverity-s-real-world-data-to-transform-clinical-trial-design-and-analytics 2025-04-16T20:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/906fd8e1bb667be4/capricorn-scientific-and-florabio-partner-to-advance-animal-free-cell-culture-media-for-biotech-industry 2025-04-16T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/6179774a0a77231e/mural-therapeutics-discontinues-nemvaleukin-program-and-cuts-90-of-workforce-following-clinical-setback 2025-04-16T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/dd4ca5cafdacbaaa/nanostics-secures-cpsa-accreditation-for-relocated-prostate-cancer-diagnostic-lab-in-edmonton 2025-04-16T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/7c77dbeeca3ab9ce/accent-therapeutics-initiates-phase-i-ii-trial-of-novel-kif18a-inhibitor-for-advanced-solid-tumors 2025-04-16T17:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/9a3bdbc6e80b55c4/cmg-pharmaceutical-secures-fda-approval-for-film-type-schizophrenia-treatment-mezofy 2025-04-16T17:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/32936f427d135d08/aptar-launches-clinical-study-to-validate-smarttracktm-platform-for-accelerating-generic-inhaler-approvals 2025-04-16T17:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/ceb88d376889d4b7/abu-dhabi-partners-with-novartis-to-advance-genomics-research-and-precision-medicine 2025-04-16T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/e09b5e7542a5f9c8/fda-approves-valtoco-nasal-spray-for-seizure-clusters-in-children-ages-2-5 2025-04-16T17:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/490c246a606068d6/johnson-johnson-completes-first-surgeries-with-ottava-robotic-system-in-clinical-trial 2025-04-16T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/1c0b33cd67b1a9d7/clear-oasis-9-trial-colchicine-and-spironolactone-show-limited-benefits-after-myocardial-infarction 2025-04-16T17:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/2a4cd38574a6dc85/oak-hill-bio-advances-rugonersen-for-angelman-syndrome-following-promising-phase-1-results-published-in-nature-medicine 2025-04-16T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/c8661d0b19e2287b/machine-learning-models-using-systemic-inflammation-markers-predict-neoadjuvant-chemotherapy-response-in-breast-cancer 2025-04-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6647d983893037be/eli-lilly-ceo-david-ricks-tops-pharma-executive-compensation-at-29-2-million-in-2024 2025-04-16T15:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6a810f3c4779586/glycomine-secures-115m-series-c-funding-to-advance-novel-treatment-for-pmm2-cdg-rare-disease 2025-04-16T15:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/1d340006516222cc/msd-and-cyprumed-forge-493-million-deal-to-advance-oral-peptide-therapeutics 2025-04-16T14:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/1408d5889f22f85f/biovie-launches-sunrise-pd-trial-to-test-novel-anti-inflammatory-approach-for-early-parkinson-s-disease 2025-04-16T14:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/31771278af26270d/study-reveals-significant-diagnostic-delays-for-minority-patients-with-generalized-myasthenia-gravis 2025-04-16T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/74f34cc2be3abb67/sglt2-inhibitors-demonstrate-significant-renal-benefits-in-heart-failure-and-chronic-kidney-disease 2025-04-16T14:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/5f7342cbb42c660b/pgxai-launches-deneb-ai-model-to-revolutionize-drug-development-through-pharmacogenetics 2025-04-16T14:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/ee38fd18e5f8c649/ritedose-doubles-vial-packaging-capacity-with-new-syntegon-line-to-support-ohtuvayre-copd-drug-production 2025-04-16T14:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/d1cac3e2c595f5a7/kras-inhibitors-market-set-to-exceed-2-billion-by-2030-with-next-generation-therapies-advancing 2025-04-16T14:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/fc0bd40292f7fa3a/cellino-and-karis-bio-partner-to-develop-first-autologous-ipsc-therapy-for-cardiovascular-disease 2025-04-16T13:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/a29a9e33f9c587f4/octave-s-msda-test-transforms-ms-care-with-biomarker-driven-insights 2025-04-16T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fae340d9dd0b3cf0/fda-approves-ct-132-first-digital-therapeutic-for-episodic-migraine-prevention 2025-04-16T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/09279dc16474a9cf/datchat-secures-european-patent-allowance-for-advanced-digital-privacy-technology 2025-04-16T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ae2f335ed71f347/thirtyfivebio-secures-bridge-financing-to-advance-novel-gpr35-inhibitor-for-ulcerative-colitis-treatment 2025-04-16T08:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/17b978e26bedf703/naya-therapeutics-regains-independence-to-advance-first-in-class-cancer-immunotherapies-with-2025-2026-clinical-milestones 2025-04-16T08:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/e0981bdbf4925086/autonomix-medical-secures-european-patent-for-neuromodulation-technology-targeting-cancer-pain 2025-04-16T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5c4f669741767aa/new-heart-failure-treatment-protocol-reduces-mortality-by-nearly-two-thirds-in-uk-hospitals 2025-04-16T08:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/c638f097c5e2d305/luma-vision-s-verafeye-4d-cardiac-imaging-system-receives-fda-clearance 2025-04-16T08:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/45db84bee14f1952/fda-authorizes-breakthrough-tango-belt-device-that-reduces-hip-fractures-by-91-in-older-adults 2025-04-16T06:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/82ce73a6abf5d811/fda-clears-ceribell-s-ai-algorithm-for-pediatric-seizure-detection-in-patients-as-young-as-one-year-old 2025-04-16T05:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/530559b8cda35127/fda-approves-abeona-s-novel-cell-therapy-for-rare-skin-disease 2025-04-16T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/8a5b593e0b59740b/ziresovir-shows-breakthrough-efficacy-against-rsv-in-infants-under-6-months-with-long-term-benefits 2025-04-16T05:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/9fc552830d50a800/fda-grants-fast-track-designation-to-prescient-s-ptx-100-for-cutaneous-t-cell-lymphoma-treatment 2025-04-16T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/44a6c60bdf9c6bde/biocon-biologics-secures-settlement-with-regeneron-to-launch-aflibercept-biosimilar-in-us-by-2026 2025-04-16T05:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/d789cea1da150bda/real-world-evidence-validates-proenkephalin-a-119-159-as-superior-kidney-function-biomarker-in-critical-care 2025-04-16T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/57b039342faae23a/tevogen-bio-partners-with-databricks-to-advance-ai-driven-immunotherapy-target-prediction-platform 2025-04-16T02:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/780f94a952f758ef/adar1-gene-identified-as-key-driver-of-lenalidomide-resistance-in-multiple-myeloma 2025-04-16T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/c3692a75f40d226d/dm-clinical-research-partners-with-florida-sleep-specialists-to-advance-obesity-and-sleep-disorder-treatments 2025-04-16T02:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/8be6df16fa6a9f6d/scipher-medicine-and-kythera-labs-form-strategic-partnership-to-advance-precision-medicine-in-rheumatology 2025-04-16T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/9d4805caaf03e09e/turing-medical-appoints-kevin-king-as-ceo-to-advance-brain-mapping-technology-and-depression-treatment 2025-04-16T00:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/1516b83e88a04323/fda-approves-lenmeldy-4-25-million-gene-therapy-for-rare-childhood-disease-mld 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5d69f5b538d034f/bluerock-therapeutics-reports-promising-18-month-data-from-phase-1-parkinson-s-cell-therapy-trial-in-nature-publication 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/10bf76796ef89c9f/abu-dhabi-s-m42-invests-in-juvenescence-to-advance-ai-driven-longevity-research 2025-04-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6e21b86369e05297/neonc-technologies-strengthens-competitive-edge-with-176-patent-global-portfolio 2025-04-15T23:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/cb7569bc01072b51/boehringer-ingelheim-and-cue-biopharma-partner-on-novel-b-cell-targeting-therapy-for-autoimmune-diseases 2025-04-15T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/910d8754fed0604b/repurposed-blood-pressure-drug-shows-promise-for-treating-inherited-retinal-diseases-with-sex-specific-benefits 2025-04-15T23:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/4984692be366d208/metavia-s-novel-dual-receptor-agonist-shows-promising-6-3-weight-loss-in-phase-1-obesity-trial 2025-04-15T23:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/9970017df2203984/qiagen-to-launch-three-new-sample-preparation-instruments-by-2026-expanding-lab-automation-capabilities 2025-04-15T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/29259b108ced34c1/fda-grants-rmat-designation-to-iltamiocel-for-post-cancer-treatment-dysphagia 2025-04-15T20:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/e28b67ba8edf0fb6/galmed-discovers-novel-blood-biomarkers-for-aramchol-expanding-therapeutic-potential-beyond-mash 2025-04-15T20:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/e299b0e90d792879/illumina-and-tempus-join-forces-to-advance-precision-medicine-through-ai-powered-genomics 2025-04-15T20:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/7f29a7d44d875780/fda-grants-rmat-designation-to-lyell-s-dual-targeting-car-t-cell-therapy-lyl314-for-relapsed-refractory-lbcl 2025-04-15T20:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/ea8c088df0c7a8c0/ssc-ild-market-projected-to-reach-750-million-by-2034-as-novel-therapies-enter-pipeline 2025-04-15T20:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/4aaf34baabb7c424/fda-clears-ind-for-genetically-engineered-porcine-liver-system-to-treat-acute-on-chronic-liver-failure 2025-04-15T20:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/ac0beafc2c54946f/fda-approves-xellsmart-s-ipsc-derived-cell-therapies-for-parkinson-s-disease-and-als-clinical-trials 2025-04-15T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/fc1742c7a5ae07fe/neuphoria-advances-dual-clinical-programs-with-merck-partnership-milestone-and-phase-3-sad-trial-progress 2025-04-15T17:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/5fb830e5a818b2b4/abu-dhabi-launches-multi-partner-initiative-to-advance-precision-medicine-and-genomic-healthcare 2025-04-15T17:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/f38373c8ab0deab3/spruce-biosciences-acquires-tralesinidase-alfa-for-sanfilippo-syndrome-type-b-treatment-with-bla-submission-planned-for-2026 2025-04-15T17:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/1a4a81cd8702ad0b/dyne-therapeutics-strengthens-leadership-team-with-key-scientific-and-business-appointments 2025-04-15T17:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/e797f64d21f01c96/fda-approves-terumo-neuro-s-first-in-class-dual-layer-micromesh-carotid-stent-system 2025-04-15T17:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/4fbb081725032d82/rege-nephro-acquires-tamibarotene-assets-from-syros-pharmaceuticals-for-adpkd-development 2025-04-15T17:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/17882e4218650f96/mytomorrows-and-scout-clinical-launch-partnership-to-revolutionize-cross-border-clinical-trial-recruitment 2025-04-15T17:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/af0d7241ec6979ff/novavax-covid-19-vaccine-shows-fewer-side-effects-than-pfizer-biontech-in-shield-utah-study 2025-04-15T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/42682bb959b45826/fda-and-novo-nordisk-alert-consumers-to-counterfeit-ozempic-in-u-s-market 2025-04-15T15:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/f563461809989486/uae-partnership-to-slash-car-t-cancer-therapy-costs-by-90-through-local-manufacturing 2025-04-15T14:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/81dcf4966026113d/new-sustained-release-flucytosine-enters-phase-ii-trials-for-cryptococcal-meningitis-amid-hiv-funding-crisis 2025-04-15T14:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/843dbae918b32ef3/nimacimab-tirzepatide-combination-achieves-over-30-weight-loss-in-preclinical-obesity-study 2025-04-15T14:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/eda383efe9444b07/baylink-biosciences-to-present-novel-adc-platform-data-for-cancer-treatment-at-aacr-2025 2025-04-15T14:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/d1c521eeb40537c9/crispr-gene-editing-advances-car-nk-cell-therapy-to-overcome-clinical-bottlenecks 2025-04-15T14:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/47abc952e845a1b9/genmab-reports-strong-q1-2025-darzalex-sales-of-3-24-billion-demonstrating-continued-market-dominance 2025-04-15T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/1492fa3bde4c73ab/third-harmonic-bio-stockholders-approve-liquidation-plan-as-thb335-shows-85-tryptase-reduction-in-phase-1-trial 2025-04-15T12:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/34d83b6f428d430c/norgine-expands-rare-disease-portfolio-with-strategic-acquisition-of-theravia 2025-04-15T11:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/800d4fe4119f4ae0/coherus-biosciences-completes-558-4-million-udenyca-divestiture-to-intas-pivots-to-oncology-focus 2025-04-15T11:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/d66deebc3aa375df/sanofi-advances-respiratory-pipeline-with-promising-amlitelimab-data-in-heterogeneous-inflammatory-asthma 2025-04-15T11:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/ed37d1a79cf52681/fda-clears-corxel-s-phase-ii-trial-for-oral-glp-1-receptor-agonist-cx11-in-obesity-treatment 2025-04-15T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/e52c2c487bfb96c0/geovax-advances-multi-antigen-covid-19-vaccine-and-expands-oncology-pipeline-despite-barda-setback 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2df8f3fa7391e42/evommune-s-mrgprx2-antagonist-evo756-shows-promise-in-chronic-urticaria-trials 2025-04-15T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbcdc02d64483b43/vascarta-launches-first-human-trial-of-transdermal-curcumin-therapy-for-sickle-cell-disease 2025-04-15T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/008dcfbce215d6c1/imperative-care-launches-first-randomized-trial-of-aspiration-thrombectomy-for-m2-stroke-occlusions 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec8295c08e192aa8/fluidform-bio-achieves-breakthrough-in-vascularized-tissue-engineering-for-diabetes-treatment 2025-04-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f44aa905583248a/galapagos-cfo-and-coo-thad-huston-to-depart-as-company-advances-cell-therapy-transformation 2025-04-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/edfdca716e75e8fa/heparegenix-secures-eur21-5-million-to-advance-novel-liver-regeneration-therapy 2025-04-15T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e761bbc451fc0e8/breakthrough-in-colorectal-cancer-drug-discovery-novel-nano-delivery-systems-and-precision-therapy-targets-identified 2025-04-15T01:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/ed0b91b72b7f5bf1/fda-approves-first-lupus-nephritis-treatment-gsk-s-benlysta-autoinjector-for-pediatric-patients 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/573c479717b92954/tvardi-therapeutics-completes-merger-with-cara-advances-stat3-inhibitor-programs-for-fibrosis-driven-diseases 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0fbe935ce1a8c06/j-j-raises-2025-sales-forecast-despite-400m-tariff-impact-following-intra-cellular-acquisition 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/942c08b26e6492e0/ripretinib-demonstrates-efficacy-as-neoadjuvant-therapy-for-gist-in-first-case-report 2025-04-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aadc25e709ed3fc9/chromatin-bioscience-and-astellas-partner-to-develop-cell-selective-synthetic-promoters-for-precision-gene-expression 2025-04-14T21:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/fd5aa15f9fc64511/edwards-lifesciences-secures-first-ce-mark-for-transfemoral-mitral-valve-replacement-system 2025-04-14T21:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/dd16c3ee060f09ca/scancell-partners-with-nhs-to-fast-track-promising-cancer-vaccine-trial 2025-04-14T21:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/db2b59d85ba1724b/fda-grants-conditional-approval-for-carmat-s-aeson-artificial-heart-second-cohort-study 2025-04-14T20:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/2f159ea1267104fc/sohum-health-launches-nih-funded-clinical-trial-comparing-buprenorphine-formulations-for-rural-opioid-use-disorder-treatment 2025-04-14T18:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/d80e17a8af4fb783/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-until-2040 2025-04-14T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2767c8003733e4b/certara-launches-non-animal-navigator-solution-to-reduce-animal-testing-in-drug-development 2025-04-14T17:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/3fff349abd7a2c90/fda-issues-warning-for-zoetis-canine-osteoarthritis-drug-librela-after-reports-of-serious-adverse-reactions 2025-04-14T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8af73f9b83e6a59/precision-medicine-biologics-poised-to-transform-30-2-billion-copd-market-by-2033 2025-04-14T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/3c4f0c25c4e9d292/inmune-bio-partners-with-cgt-catapult-to-scale-cordstrom-manufacturing-for-rare-skin-disease-treatment 2025-04-14T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/b25a3ef9dd25c16b/ironwood-pharmaceuticals-faces-setback-as-fda-requires-additional-phase-3-trial-for-apraglutide 2025-04-14T17:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/c171e8125e5035f3/reveal-genomics-and-ona-therapeutics-partner-to-advance-novel-adc-cancer-treatment-with-biomarker-strategy 2025-04-14T17:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/0abbdd579891311d/jama-oncology-study-confirms-oncotype-dx-test-effectiveness-across-all-racial-and-ethnic-groups 2025-04-14T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/5530e04da235d038/pheast-therapeutics-initiates-phase-1-trial-of-novel-anti-cd24-macrophage-checkpoint-inhibitor-for-advanced-solid-tumors 2025-04-14T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/5ed01d5588df5edb/ironwood-pharmaceuticals-faces-setback-in-apraglutide-development-for-short-bowel-syndrome 2025-04-14T14:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/e26e520e50b565d6/scancell-and-nhs-partner-to-accelerate-melanoma-vaccine-trial-recruitment 2025-04-14T14:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/3514be2df278b8ee/can-fite-biopharma-secures-3-million-in-funding-to-advance-clinical-trials-for-oncology-and-inflammatory-disease-treatments 2025-04-14T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/8363799142b2fe1b/synact-pharma-launches-phase-ii-trial-of-resomelagon-for-dengue-treatment-in-brazil 2025-04-14T14:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/cff050a58074406f/fda-approves-bruno-vision-care-s-revolutionary-deseyne-contact-lenses-with-controlled-release-hydration-technology 2025-04-14T14:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/19ad6d6a802ac3e0/lobe-sciences-secures-6m-private-placement-for-novel-conjugated-psilocin-development-in-chronic-cluster-headache 2025-04-14T14:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/5752157ab3940345/cspc-pharmaceutical-s-sys6041-and-syh2046-receive-fda-approval-for-clinical-trials 2025-04-14T14:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/aded130e3fd0d1f4/fda-grants-orphan-drug-designation-to-cellenkos-ck0801-for-aplastic-anemia-treatment 2025-04-14T14:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/9bbacc965c593071/ainos-advances-veldona-oral-interferon-platform-with-dual-clinical-trial-approvals-for-rare-diseases 2025-04-14T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/550e3cff1e894e18/once-weekly-insulin-icodec-combined-with-cgm-shows-promising-results-for-type-2-diabetes-management 2025-04-14T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/026b8793f7e73031/elix-and-prism-biolab-partner-to-revolutionize-drug-discovery-for-protein-protein-interaction-targets 2025-04-14T11:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/8ae394e0cf198f1d/fda-approves-bms-s-opdivo-yervoy-combination-for-first-line-treatment-of-advanced-liver-cancer 2025-04-14T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/43801ba35267a00f/dea-under-fire-for-seven-year-delay-in-medical-marijuana-research-application 2025-04-14T11:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/7ac700e37c195ff9/sandoz-files-antitrust-lawsuit-against-amgen-to-unlock-access-to-etanercept-biosimilar-in-us-market 2025-04-14T07:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/fdf4e9c85b2368f6/sun-pharma-s-leqselvi-advances-toward-launch-after-favorable-us-court-ruling 2025-04-14T07:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/03e453d72feaa8ea/cms-proposes-ntap-for-sequana-medical-s-alfapump-system-boosting-medicare-access-for-cirrhosis-patients 2025-04-14T07:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fc55af87dba167a0/genflow-biosciences-partners-with-heureka-labs-to-accelerate-sirt6-gene-therapy-development-using-ai 2025-04-14T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/2610043aa0a5f131/acro-biomedical-secures-taiwanese-approval-for-novel-collagen-ophthalmic-matrix-to-address-global-corneal-transplant-shortage 2025-04-14T04:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/6161bf6f6875e976/fda-approves-datopotamab-deruxtecan-for-previously-treated-egfr-mutated-nsclc 2025-04-14T02:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/c84bf7630eaa3b68/nhs-expands-cancer-vaccine-launch-pad-to-include-promising-melanoma-treatment 2025-04-14T01:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/0868c2452f594470/proqr-therapeutics-bolsters-leadership-team-with-strategic-cfo-and-cmo-appointments-as-rna-editing-platform-advances-to-clinical-stage 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/54fc9e4a94313be4/tirzepatide-emerges-as-most-effective-glp-1-agonist-for-diabetes-and-weight-loss-rapidly-overtaking-traditional-therapies 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0996b46325e883d1/immunotherapy-enhanced-total-neoadjuvant-therapy-shows-promise-for-locally-advanced-rectal-cancer 2025-04-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/647ff81c822724a7/zydus-healthcare-secures-cdsco-approval-for-phase-iii-trials-of-two-copd-combination-therapies 2025-04-13T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/377ae2dba6c31fcb/ugandan-scientist-secures-us-patent-for-revolutionary-cancer-treatment-using-crispr-technology 2025-04-13T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/c5663fd39eef308a/lift-biosciences-appoints-dr-mark-exley-as-cso-to-advance-novel-neutrophil-therapy-into-clinical-trials 2025-04-13T22:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/4c524ea0e18eb413/oncodesign-services-appoints-dr-aidan-synnott-as-ceo-to-strengthen-drug-discovery-partnerships 2025-04-13T10:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/c550ecb7a0fbdb6d/annexon-s-tanruprubart-shows-rapid-and-durable-improvements-in-guillain-barre-syndrome-phase-iii-trial 2025-04-12T23:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/61dca7711a2ba1f6/abu-dhabi-successfully-completes-first-stem-cell-trial-for-knee-osteoarthritis-with-promising-results 2025-04-12T22:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/0dd8864657d5fd4b/wockhardt-s-novel-antibiotic-zaynich-expected-to-receive-usfda-approval-in-2025 2025-04-12T22:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/9fb6d4b95bb974df/plasma-based-mrd-analysis-shows-promise-for-predicting-recurrence-in-egfr-mutant-nsclc-following-osimertinib-treatment 2025-04-12T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/15dff0963c3e9dfc/certolizumab-therapy-shows-breakthrough-results-for-high-risk-pregnancies-in-antiphospholipid-syndrome 2025-04-12T17:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/6be9e5892d4f075d/omeros-forms-elite-clinical-steering-committee-to-advance-novel-aml-therapeutic-program 2025-04-12T14:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/51656df656896bcb/fda-phases-out-animal-testing-requirement-for-monoclonal-antibodies-and-other-drugs 2025-04-12T13:40:38+00:00 hourly 0.9 https://trial.medpath.com/news/299ed64c3b61be38/conduit-pharmaceuticals-files-novel-cocrystal-patent-for-vtama-extending-therapeutic-potential-beyond-2027 2025-04-12T13:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/8589f20bb5b8f815/cms-policy-changes-create-new-reimbursement-challenges-for-505-b-2-oncology-drugs 2025-04-12T13:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/1cc8b207df15ea7b/usc-study-confirms-safety-profile-of-covid-19-treatments-paxlovid-and-other-antivirals-show-minimal-serious-side-effects 2025-04-12T05:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/096b8bce20240374/aurobindo-pharma-s-us-subsidiary-receives-11-fda-observations-following-inspection 2025-04-12T03:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad66ff20b6c52de7/onesource-s-bengaluru-facility-secures-anvisa-gmp-approval-opening-doors-to-brazilian-market 2025-04-12T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/e0021a31f8a40d9b/fda-approves-ide-for-innoblative-s-sira-device-to-transform-breast-cancer-surgery 2025-04-11T23:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/1bc69c354c25acee/first-canadian-patient-receives-personalized-mrna-therapy-for-bladder-cancer-in-muhc-trial 2025-04-11T23:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/ac4cade4a75fc802/coologics-launches-multi-center-trials-for-novel-cooling-device-to-treat-vaginal-yeast-infections 2025-04-11T23:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/3bbfc68240d292b1/cellistic-launches-echo-nk-platform-for-scalable-allogeneic-nk-cell-therapy-manufacturing 2025-04-11T21:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/405c83d05dc26f48/solvonis-therapeutics-completes-acquisition-of-awakn-life-sciences-in-46-67-share-exchange-deal 2025-04-11T20:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/d317db5222d3ac76/tavapadon-shows-promise-in-phase-3-trials-for-parkinson-s-disease-with-improved-motor-function-and-safety-profile 2025-04-11T17:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/dba998c8a22b4d2f/fda-approves-simplified-dosing-regimen-for-acetadote-to-enhance-acetaminophen-overdose-treatment 2025-04-11T17:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/a5efef0e98863cf8/vantage-biosciences-initiates-phase-2-trial-of-novel-oral-therapy-for-diabetic-retinopathy 2025-04-11T15:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/396bb48af2b90267/fda-grants-ide-approval-for-innoblative-s-novel-electrosurgical-device-for-breast-cancer-treatment 2025-04-11T14:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/e8a79a89fd51bfab/titan-pharmaceuticals-secures-1-6-million-in-strategic-funding-through-two-convertible-preferred-stock-placements 2025-04-11T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/f89144bc80ce092c/impact-biotech-to-present-promising-data-on-padeliporfin-vtp-for-utuc-and-prostate-cancer-at-aua-2025 2025-04-11T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/236457a7947ee6ba/fda-announces-shift-from-animal-testing-to-ai-models-boosting-recursion-pharmaceuticals-stock-20 2025-04-11T11:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7a5e0d2ec716cef/new-liver-directed-treatment-shows-promising-results-for-metastatic-uveal-melanoma 2025-04-11T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/1d4def32ac131cf9/cipla-receives-usfda-approval-for-generic-version-of-cancer-drug-abraxane 2025-04-11T09:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/9b08b30074dd2967/south-korea-approves-world-s-first-recombinant-anthrax-vaccine-barythrax 2025-04-11T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b165cb102752607/phenylketonuria-pipeline-shows-robust-growth-with-25-therapies-in-development 2025-04-11T08:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/eaa73b508b638af1/johnson-johnson-reports-positive-results-from-phase-iii-trial-of-new-plaque-psoriasis-treatment 2025-04-11T07:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/24b2c34fe187ceaa/engineered-invisible-brain-cells-reverse-parkinson-s-symptoms-in-preclinical-study 2025-04-11T06:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/3682452e324ca673/epsilogen-acquires-tigatx-to-create-leading-pan-isotype-cancer-antibody-company 2025-04-11T05:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/d31c942126111a09/briapro-develops-novel-antibodies-targeting-b7-h3-for-multi-cancer-immunotherapy-applications 2025-04-11T05:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/cb62747a8d9b96cc/turbett-surgical-secures-fda-510-k-clearance-for-enhanced-instrument-pod-systems-with-increased-capacity 2025-04-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58dae215ee15c101/fibrobiologics-opens-new-houston-laboratory-to-accelerate-fibroblast-based-therapeutics-development 2025-04-11T03:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/1d82d5671e7335ff/fda-to-phase-out-animal-testing-requirement-for-monoclonal-antibodies-and-drugs 2025-04-11T02:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/af1608afaad3c880/arpa-h-awards-29-million-to-ginkgo-bioworks-consortium-for-revolutionary-wheat-based-pharmaceutical-manufacturing 2025-04-11T02:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/4755239b6b6d0d85/breakthrough-breast-cancer-drug-capivasertib-approved-for-nhs-use 2025-04-11T02:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/9fd1a9fd8f2d61d7/fda-approves-pre-filled-syringe-for-self-injection-of-efgartigimod-in-gmg-and-cidp-patients 2025-04-11T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/97a84a0a7b3950df/novartis-announces-23-billion-investment-to-expand-us-manufacturing-and-r-d-footprint 2025-04-11T02:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/7aba441e7535d1b6/hebrew-university-develops-revolutionary-xha-based-antibiotic-eyedrops-with-potential-for-human-applications 2025-04-11T01:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/b7033c244c28395f/fda-clears-first-stapler-for-single-port-robotic-surgery-with-da-vinci-sp-system 2025-04-11T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/0a6c2e906e9311bc/inspire-trials-computerized-alerts-improve-antibiotic-selection-in-hospitalized-patients-by-up-to-35 2025-04-11T01:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/f921aae1af0be739/thriva-and-tasso-partner-to-revolutionize-blood-testing-for-needle-phobia-sufferers 2025-04-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae7c03966e587d2e/sanofi-s-amlitelimab-shows-promising-results-in-atopic-dermatitis-trial-following-1-45bn-kymab-acquisition 2025-04-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5630e030e397245b/fda-plans-to-phase-out-animal-testing-requirements-boosting-health-tech-stocks 2025-04-10T23:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/da02646c0bb5f9ba/cefiderocol-shows-higher-efficacy-when-used-earlier-in-treatment-of-serious-gram-negative-infections 2025-04-10T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/911a5912e2a615a2/omilancor-outperforms-anti-tl1a-therapies-in-ibd-treatment-shows-promise-for-severe-ulcerative-colitis 2025-04-10T22:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/0c264df62735da41/daxor-submits-fda-510-k-for-next-generation-blood-volume-analyzer-with-enhanced-point-of-care-capabilities 2025-04-10T21:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/ab6589e258915c35/immunitybio-secures-75-million-in-equity-financing-to-advance-immunotherapy-pipeline 2025-04-10T21:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/20504a129cfcde69/lundbeck-s-vyepti-demonstrates-sustained-efficacy-in-migraine-prevention-at-aan-2025 2025-04-10T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/875b249dc30aae9a/pridopidine-shows-promising-long-term-benefits-for-huntington-s-disease-patients-not-on-antidopaminergic-medications 2025-04-10T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/1c25cd4200a5977e/okeiro-secures-eur10-million-to-advance-ai-driven-precision-medicine-platform-for-transplantation-and-chronic-diseases 2025-04-10T20:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/fa9f27c237a61b73/genflow-biosciences-launches-novel-sirt6-gene-therapy-program-for-eye-diseases 2025-04-10T20:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/6fe2fa588c88dddc/myasthenia-gravis-market-set-to-reach-10-3-billion-by-2034-driven-by-seven-late-stage-pipeline-therapies 2025-04-10T20:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/69aa03304a13ae03/pasithea-s-pas-004-shows-strong-target-engagement-with-91-perk-inhibition-in-phase-1-cancer-trial 2025-04-10T20:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/e9f9ef349cca415a/pykus-therapeutics-completes-enrollment-for-novel-retinal-detachment-treatment-trial 2025-04-10T20:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/fc9a69f357df2de0/4basebio-secures-uk-regulatory-license-for-gmp-grade-synthetic-dna-production 2025-04-10T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/c77dcf5ce1e0c953/tempest-therapeutics-seeks-partner-for-phase-iii-liver-cancer-drug-amezalpat-amid-funding-challenges 2025-04-10T18:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/2618a4d51a562da1/rivus-pharmaceuticals-strengthens-leadership-team-ahead-of-critical-phase-2b-mash-trial-results 2025-04-10T18:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/cdf2a5332a8e2970/palatin-s-melanocortin-agonist-shows-promising-results-in-phase-2b-diabetic-kidney-disease-trial 2025-04-10T17:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/67887aa6d260269d/cytora-s-stem-cell-therapy-shows-promising-results-for-diabetic-foot-ulcers-in-phase-1-2a-trial 2025-04-10T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/0b780fc3cf78cd70/china-approves-first-hemophilia-b-gene-therapy-bbm-h901-shows-promising-results-in-single-dose-treatment 2025-04-10T17:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/fe867b6b811e2776/shilpa-medicare-s-raichur-unit-2-achieves-second-consecutive-zero-observation-fda-inspection 2025-04-10T17:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/c79513316d1aaf30/brainstorm-advances-nurown-als-therapy-with-fda-aligned-phase-3b-trial-submission 2025-04-10T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/b1eb7f6fdb586923/galmed-reports-promising-results-for-aramchol-meglumine-formulation-in-phase-1-bioavailability-study 2025-04-10T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/95e3c4106f4c5f10/circular-rnas-emerge-as-promising-biomarkers-and-therapeutic-targets-in-colorectal-cancer-immunotherapy 2025-04-10T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc208d963b484f5a/hebe-biotechnology-appoints-dr-hannes-hentze-as-cdo-to-advance-novel-glp-1-weight-loss-therapy 2025-04-10T15:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/baaa885f4f530be5/three-pharmaceutical-companies-advance-next-generation-covid-19-therapeutics-in-clinical-trials 2025-04-10T14:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/53bbb3522e9d05eb/oculis-completes-enrollment-in-phase-3-diamond-trials-for-first-ever-topical-dme-treatment 2025-04-10T14:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/4d16e9a80097bd06/tempest-therapeutics-seeks-strategic-partner-for-promising-liver-cancer-drug-amezalpat-amid-funding-challenges 2025-04-10T14:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/acf2b5bc5f3154b7/ps10m-investment-in-ai-powered-robotic-labs-to-accelerate-infectious-disease-treatment-development 2025-04-10T14:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/74468ec9aa0f20c7/first-patient-dosed-in-phase-1-2-trial-of-ksq-004ex-crispr-engineered-til-therapy-for-advanced-solid-tumors 2025-04-10T14:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/c27ad5d34b95743f/theriva-biologics-presents-phase-1b-2a-safety-data-for-syn-004-in-hematopoietic-cell-transplant-recipients-at-escmid-global 2025-04-10T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d8380a3694d5eac/amacathera-partners-with-global-pharmaceutical-company-to-develop-single-injection-biologic-using-amacagel-platform 2025-04-10T11:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/e87efca9c09f50f1/u-s-court-ruling-clears-path-for-sun-pharma-s-alopecia-drug-leqselvi-launch 2025-04-10T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/9cecd7e9d8ed8748/fda-approves-biocon-biologics-bevacizumab-biosimilar-jobevne-for-multiple-cancer-indications 2025-04-10T11:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/2410e5c89dbae11a/aprocitentan-shows-significant-blood-pressure-and-proteinuria-reduction-in-black-patients-with-resistant-hypertension 2025-04-10T08:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/e62e904c135838e3/telo-genomics-multiple-myeloma-mrd-validation-data-accepted-for-asco-2025-annual-meeting 2025-04-10T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f5da9f70f15e93c/recce-pharmaceuticals-secures-a-15-8-million-to-advance-phase-iii-trials-for-novel-anti-infectives 2025-04-10T08:03:07+00:00 hourly 0.9 https://trial.medpath.com/news/56409306cd1663fd/robust-pipeline-of-80-therapies-advancing-in-psoriasis-treatment-landscape 2025-04-10T08:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/1bd31a4154fdb683/swinburne-university-and-tryptamine-therapeutics-launch-world-first-intravenous-psilocin-trial-for-binge-eating-disorder 2025-04-10T08:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/0a08570d4417d33a/ai-and-data-collaboration-key-to-advancing-cell-therapy-in-biopharma-industry 2025-04-10T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aec74b327b089169/city-of-hope-researchers-discover-novel-approach-to-target-pancreatic-cancer-s-genetic-vulnerability 2025-04-10T05:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/2448ee40c99264af/northstrive-biosciences-advances-ai-powered-drug-discovery-for-obesity-and-cardiac-diseases 2025-04-10T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/45c1732c8abdf30b/tonsil-removal-reduces-healthcare-needs-in-children-with-mild-sleep-disordered-breathing 2025-04-10T04:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/eb8baa2e8bf78b00/teen-substance-use-remains-at-historic-lows-in-2024-nih-survey-reveals 2025-04-10T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/a6b1fb270b5f2773/bipartisan-bill-proposes-national-biotechnology-coordination-office-to-counter-china-s-growing-influence 2025-04-10T03:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/2145f28a5f907293/european-launch-sequencing-challenges-industry-experts-debate-solutions-at-reuters-pharma-europe-2025 2025-04-10T03:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/83ce414fb2116194/kandu-health-and-neurolutions-merge-to-create-comprehensive-stroke-recovery-platform-with-30m-financing 2025-04-10T02:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/e0a04520fb0a5003/acurion-launches-ai-powered-platform-to-revolutionize-precision-oncology-diagnostics 2025-04-10T02:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/1c226b658e24c32e/real-world-evidence-oncology-market-projected-to-reach-3-51-billion-by-2035-with-14-7-cagr 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/2802f228ff956d1b/adlai-nortye-to-showcase-novel-cancer-immunotherapy-and-ras-inhibitor-at-aacr-2025 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3a0a0b8799b85af/bluerock-therapeutics-partners-with-digital-health-companies-to-advance-parkinson-s-disease-clinical-trials 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/43b5d2a846d78694/decade-long-uk-registry-reveals-key-insights-into-idiopathic-pulmonary-fibrosis-management-and-future-directions 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd0a380e9f4fb915/liso-cel-combined-with-ibrutinib-shows-promise-for-relapsed-refractory-cll-and-richter-transformation 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/96dcad8966496af0/dual-modal-approach-combining-oct-and-raman-spectroscopy-achieves-97-accuracy-in-skin-cancer-detection 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/87369cf0c2987d40/uk-government-unveils-life-sciences-strategy-to-strengthen-post-brexit-industry 2025-04-10T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a968ed2153f26784/pacira-biosciences-secures-future-of-exparel-with-strategic-patent-settlement-agreement 2025-04-09T23:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/0300398dc0f05357/curateq-biologics-denosumab-biosimilar-meets-primary-endpoints-in-phase-1-study 2025-04-09T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/2b829d32a1b88f52/sunlight-trial-highlights-importance-of-sequential-therapies-in-refractory-colorectal-cancer 2025-04-09T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/f509ab6519509c93/sodium-channel-blockers-pipeline-surges-with-20-pharmaceutical-companies-developing-novel-therapies 2025-04-09T21:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/a8b9b3ce9394e85f/carmat-reports-strong-q1-2025-results-with-140-increase-in-aeson-r-artificial-heart-implants 2025-04-09T21:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/077f917fa83a00d2/jazz-and-hikma-to-pay-195m-to-settle-antitrust-claims-over-narcolepsy-drug-xyrem 2025-04-09T20:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/f1e4faa89b922d9e/merida-biosciences-launches-with-121m-to-target-disease-causing-antibodies-in-autoimmune-conditions 2025-04-09T20:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/94e332a80b8081c7/addressing-the-unique-challenges-in-aya-non-hodgkin-lymphoma-care-expert-insights 2025-04-09T19:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/71a4d7c400987c23/discgenics-cell-therapy-for-degenerative-disc-disease-receives-recognition-as-phase-iii-trial-approaches 2025-04-09T16:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/db7580fade697c85/nanorobots-for-drug-delivery-market-set-to-reach-1-73-billion-by-2030-transforming-precision-medicine 2025-04-09T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/6e8be84272dde5e6/fda-clears-zeiss-intrabeam-700-advanced-robotic-assisted-platform-for-intraoperative-radiotherapy 2025-04-09T16:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/609f094736a17a93/recursion-and-enamine-launch-ai-powered-compound-libraries-to-accelerate-drug-discovery 2025-04-09T16:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/2fcfc7646e08d62f/fda-approves-b-braun-s-piperacillin-and-tazobactam-in-duplex-drug-delivery-system 2025-04-09T16:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/d7b04831d5c330ea/probio-opens-128000-square-foot-gene-therapy-manufacturing-center-in-new-jersey 2025-04-09T16:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/231cd5ae45af9872/infinitopes-secures-mhra-approval-for-phase-i-iia-trial-of-novel-cancer-vaccine-against-oesophageal-adenocarcinoma 2025-04-09T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/9bef95691cd7ca3f/nexthera-initiates-phase-1-2a-trial-of-nt-101-eye-drops-for-wet-amd-potentially-eliminating-need-for-injections 2025-04-09T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/84483368569e4628/avita-medical-to-present-new-clinical-data-on-permeaderm-for-burn-and-wound-management-at-aba-2025 2025-04-09T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/60f894b58d5699b8/sinomab-s-sm17-shows-breakthrough-results-in-phase-1b-trial-for-atopic-dermatitis 2025-04-09T14:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/9f9cb4f5db63998e/longhorn-vaccines-advances-universal-flu-vaccine-with-broad-cross-species-protection 2025-04-09T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/4376ddac1bb38118/cepheid-and-oxford-nanopore-partner-to-revolutionize-infectious-disease-sequencing-workflows 2025-04-09T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/742f9a86a0b60008/orthopediatrics-launches-fda-cleared-verteglide-system-for-early-onset-scoliosis-treatment 2025-04-09T10:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/d92bf1881f5d73ae/pridopidine-shows-promise-for-als-subgroups-in-healey-platform-trial 2025-04-09T10:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/7170af1fcf4b3e0f/first-patient-enrolled-in-nih-funded-expanded-access-program-for-mn-166-in-advanced-als 2025-04-09T10:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/c5f2519a3427e887/valneva-and-limmatech-advance-pioneering-shigella-vaccine-into-phase-2-trials 2025-04-09T08:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/cc5583923c5a677b/cdmo-market-report-key-regulatory-approvals-and-clinical-advances-in-march-april-2025 2025-04-09T08:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/2418724e30767bb2/china-s-first-monkeypox-vaccine-enters-phase-i-clinical-trials-with-diverse-volunteer-cohort 2025-04-09T08:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/61f5439965fdec3f/novo-nordisk-invests-1-09-billion-to-expand-glp-1-production-capacity-in-brazil 2025-04-09T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6f2023301ab8afa/kymera-therapeutics-appoints-noah-goodman-as-chief-business-officer-to-advance-protein-degradation-platform 2025-04-09T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/e290ace767726b33/phenomix-sciences-launches-clinical-trial-to-predict-patient-response-to-glp-1-obesity-treatments 2025-04-09T05:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/011e13abab731ac2/2025-pharmaceutical-pipeline-major-patent-expirations-set-to-transform-drug-market-with-generics-and-biosimilars 2025-04-09T05:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/2d1f1de7ce81bb8a/scientist-com-launches-clinical-labs-navigator-to-streamline-clinical-trial-management 2025-04-09T03:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/82976bfc85af7d91/astrazeneca-s-camizestrant-shows-56-reduction-in-breast-cancer-progression-risk-using-blood-test-guided-treatment 2025-04-09T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/ad3d400daf3ca503/orviglance-shows-superior-liver-lesion-detection-in-phase-ii-study-published-in-investigative-radiology 2025-04-09T02:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/a6ef7d2429d7a1b8/fda-clears-cardiovia-s-viaone-system-for-safer-access-to-heart-surface-transforming-cardiac-interventions 2025-04-09T00:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/9fe6c158320951a3/henlius-advances-world-s-first-pd-l1-adc-to-phase-2-trial-for-advanced-nsclc-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4110705f4607a290/comprehensive-safety-analysis-reveals-distinct-adverse-event-profiles-across-anti-her2-drug-classes-in-breast-cancer-treatment 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf8443b88e36e407/adaptive-clinical-trial-designs-gain-momentum-as-industry-embraces-efficiency-and-innovation 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a60509ebe3d4360/vaxess-demonstrates-needle-free-glp-1-patch-achieves-comparable-bioavailability-to-injections 2025-04-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/423ff7e33f6e6476/new-genetic-test-prostox-predicts-urinary-side-effects-from-prostate-cancer-radiation-therapy 2025-04-08T23:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/04dabc7cacc66a6d/lifemine-therapeutics-initiates-first-in-human-trial-of-novel-calcineurin-inhibitor-life-001 2025-04-08T23:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/42962c4f0072e484/breakthrough-drug-compound-prevents-long-covid-symptoms-in-mice-offering-hope-for-first-treatment 2025-04-08T23:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/4b2700deed0197e7/robust-pipeline-of-55-therapies-advancing-toward-potential-functional-cure-for-chronic-hepatitis-b 2025-04-08T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/2fb654f54dddef9a/international-psycho-oncology-society-establishes-first-world-psycho-oncology-day-to-advance-integrated-cancer-care 2025-04-08T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/773270f2062ebdab/bionova-scientific-partners-with-bionique-testing-laboratories-for-mycoplasma-testing-in-biologics-manufacturing 2025-04-08T21:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/eed758e5831cfe32/fda-workforce-cuts-lead-to-historic-drop-in-medical-device-approvals 2025-04-08T20:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/d7b70c4352af7c3a/fda-approves-theratechnologies-egrifta-sv-prior-approval-supplement-and-alpha-tau-s-trial-for-recurrent-glioblastoma 2025-04-08T20:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/5169fd36b3090ab8/lipella-completes-enrollment-in-phase-iia-trial-for-novel-oral-lichen-planus-treatment 2025-04-08T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/2f802e85c1a57974/als-drug-nu-9-shows-promising-results-for-alzheimer-s-disease-in-animal-study 2025-04-08T20:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/e80451929758f1b9/hospital-based-addiction-consultation-significantly-improves-oud-treatment-outcomes-study-shows 2025-04-08T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee624bdb9b24c36c/pfizer-withdraws-sickle-cell-drug-oxbryta-globally-following-safety-concerns 2025-04-08T18:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/b2bbbfa9fa1a6e16/pacira-biosciences-settles-exparel-patent-litigation-with-fresenius-kabi-securing-market-exclusivity-until-2030 2025-04-08T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/2ba84a2cb5d6e56b/toripalimab-induction-therapy-reduces-disease-progression-risk-by-74-in-bulky-stage-iii-nsclc 2025-04-08T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/ed0b39070c18ad60/bonyf-advances-novel-alginate-organic-denture-fixative-to-phase-3-clinical-development 2025-04-08T16:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/4debdec28cddfb9b/fda-clears-ind-for-agitated-solutions-novel-cardiac-contrast-agent-advancing-to-phase-3-trials 2025-04-08T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/685d7beca237df2a/ema-grants-orphan-drug-designation-to-comanche-biopharma-s-cbp-4888-for-preeclampsia-treatment 2025-04-08T16:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/7fd61eb9a8b06617/algernon-pharmaceuticals-secures-european-patent-for-repirinast-in-kidney-disease-treatment 2025-04-08T16:40:38+00:00 hourly 0.9 https://trial.medpath.com/news/6dd18c77695f4416/japan-grants-first-orphan-drug-designation-for-myotonic-dystrophy-type-1-to-avidity-s-del-desiran 2025-04-08T16:40:37+00:00 hourly 0.9 https://trial.medpath.com/news/9b0c1adf7c457e8d/cosmos-health-expands-global-footprint-with-300000-sky-premium-life-launch-in-albania 2025-04-08T16:39:17+00:00 hourly 0.9 https://trial.medpath.com/news/6392b37aa92a7c52/recursion-doses-first-patient-in-phase-1-trial-of-rec-3565-for-relapsed-b-cell-lymphomas 2025-04-08T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/a3552247f191fd98/science-37-achieves-second-fda-inspection-success-as-top-enroller-in-phase-3-asthma-trial 2025-04-08T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5a7060dc57ee4a6/engine-biosciences-and-eddc-form-strategic-partnership-to-develop-precision-cancer-therapies 2025-04-08T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14afc5f3db90d902/study-finds-cbd-extract-may-reduce-autism-symptoms-in-children-and-adolescents 2025-04-08T14:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/d3d6a57f2a3f2129/novel-cytokine-factory-implant-shows-promise-against-hard-to-treat-cancers 2025-04-08T13:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/98691430e9190078/bioversys-reports-strong-survival-benefit-in-phase-2-trial-of-bv100-for-carbapenem-resistant-acinetobacter-infections 2025-04-08T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/eb8aceecc54f659b/bioinvent-receives-1-million-milestone-as-takeda-advances-anti-cd83-antibody-mezagitamab-to-phase-3-for-itp 2025-04-08T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/2ff81f0cea0ba9fb/fda-delays-moderna-s-combination-flu-covid-vaccine-amid-increased-regulatory-scrutiny 2025-04-08T13:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/f186fd58d9cf1352/cerevance-s-cvn293-shows-promising-safety-profile-and-brain-penetration-in-phase-1-trial-for-neurodegenerative-diseases 2025-04-08T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a66b4b27c3223ac/ingenix-secures-eur9m-seed-funding-to-revolutionize-clinical-trials-with-ai-simulation 2025-04-08T10:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/d13b5705d10b6d3a/cytotronics-unveils-neural-application-for-pixel-platform-revolutionizing-drug-discovery-for-neurological-diseases 2025-04-08T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/680a1914e3225d6a/fda-sets-october-2025-pdufa-date-for-xspray-pharma-s-resubmitted-dasynoc-application 2025-04-08T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/6522d78615f6bd3d/realta-to-present-phase-2-clinical-data-on-novel-anti-inflammatory-therapy-for-newborn-brain-injury-at-pas-2025 2025-04-08T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/f5d7f0bf4f645e3a/alzinova-secures-funding-for-phase-ii-alzheimer-s-drug-trial-preparations 2025-04-08T07:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/f4de6980de34f396/precision-for-medicine-and-sophia-genetics-form-strategic-partnership-to-revolutionize-clinical-trials-with-ai-driven-genomic-analysis 2025-04-08T07:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/b1511860b0545a92/diabetes-pipeline-shows-robust-growth-with-200-companies-developing-novel-therapies 2025-04-08T07:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/aa0b73a70660f999/enanta-pharmaceuticals-to-present-promising-rsv-antiviral-data-at-major-european-medical-conferences 2025-04-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eebc6cced07b824d/ampreloxetine-shows-promise-for-neurogenic-orthostatic-hypotension-in-msa-patients-without-worsening-supine-hypertension 2025-04-08T04:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/2c2d4147fb5cb44b/uk-invests-ps600-million-in-health-data-research-service-to-accelerate-clinical-trials 2025-04-08T02:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/08e7812db5db0434/novo-nordisk-warns-us-price-negotiations-will-impede-research-as-three-glp-1-drugs-face-scrutiny 2025-04-08T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/fe11ddfe295db2f7/minnesota-developed-synerfuse-implant-for-chronic-back-pain-advances-toward-fda-approval 2025-04-08T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/bb0c0f6d38a4db2a/novel-chimeric-autoantibody-receptor-t-cells-show-promise-for-treating-graves-disease 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc58d3ca0bff87f5/uk-mhra-approves-trofolastat-first-psma-targeting-agent-for-prostate-cancer-imaging 2025-04-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/572e74ca96520901/acrivon-therapeutics-appoints-renowned-oncologist-dr-mansoor-raza-mirza-as-chief-medical-officer-to-lead-clinical-development 2025-04-07T22:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/b1bbf9e7e425b343/ai-discovered-drug-rentosertib-shows-promising-phase-iia-results-for-idiopathic-pulmonary-fibrosis 2025-04-07T22:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/35f497cd61940bf9/taurx-s-lmtx-shows-promising-results-for-alzheimer-s-treatment-with-potential-to-become-first-oral-disease-modifying-therapy 2025-04-07T20:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/c22ef9809cf0465b/rhythm-pharmaceuticals-imcivree-shows-significant-weight-loss-in-phase-iii-hypothalamic-obesity-trial 2025-04-07T20:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/3f45fa098d8ae8fc/agc-biologics-expands-global-cell-therapy-network-with-new-yokohama-facility-and-advanced-single-use-bioreactor-technology 2025-04-07T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b9d23ec3b79a2d2/reunion-neuroscience-to-launch-rekindle-phase-2-trial-for-adjustment-disorder-in-cancer-patients-using-psychedelic-therapy 2025-04-07T16:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/84e8494be3a9cf15/amneal-s-crexont-shows-significant-sleep-quality-improvements-in-parkinson-s-disease-patients 2025-04-07T16:43:20+00:00 hourly 0.9 https://trial.medpath.com/news/818d29771897a4b3/nih-breakthrough-personalized-immunotherapy-shows-promise-against-gastrointestinal-cancers 2025-04-07T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/c110a6b6a54a7b21/fda-clears-icu-medical-s-precision-iv-pumps-expanding-infusion-therapy-capabilities 2025-04-07T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/7ef721ebfe319b1e/dare-bioscience-fast-tracks-sildenafil-cream-launch-with-dual-market-strategy-for-women-s-health 2025-04-07T16:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/8636c74928f31493/fda-approves-avenacy-s-propofol-injectable-emulsion-as-generic-alternative-to-diprivan 2025-04-07T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/16cf795212bee749/nordic-pharma-s-canalicular-gel-lacrifill-receives-ce-mark-for-dry-eye-disease-treatment 2025-04-07T16:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/df946bb62ec582bc/rhythm-s-imcivree-shows-significant-weight-loss-in-patients-with-hypothalamic-obesity 2025-04-07T16:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ba7680912dc51b6/spatial-transcriptomics-reveals-new-therapeutic-targets-for-head-and-neck-cancer-immunotherapy 2025-04-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ee922e546dc8444/ipl344-shows-promising-results-in-slowing-als-progression-in-phase-2a-trial 2025-04-07T14:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/e06648fc7f9bfb44/adhd-medications-show-minimal-cardiovascular-effects-in-comprehensive-analysis 2025-04-07T14:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/04ec27b332d6c556/lexeo-therapeutics-partners-with-investors-to-launch-40m-rna-cardiac-therapeutics-spinout 2025-04-07T14:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/4cca877dae63ec54/fda-accepts-teva-s-application-for-ajovy-in-pediatric-migraine-prevention-potentially-first-cgrp-antagonist-for-children 2025-04-07T14:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/65c6b2c1b3a8e781/caris-life-sciences-secures-168-million-in-funding-to-advance-precision-medicine-platform 2025-04-07T13:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/4c852bdf6bfe898b/curevac-advances-novel-mrna-immunotherapy-for-squamous-non-small-cell-lung-cancer-with-fda-ind-clearance 2025-04-07T13:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/3b9ee36c57118bd3/erbc-and-menarini-biotech-form-strategic-alliance-to-accelerate-biopharmaceutical-development 2025-04-07T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6086c8e990d0d16b/biotech-leadership-shuffle-continues-as-industry-navigates-transformation-in-q2-2025 2025-04-07T10:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/5f838e1a7aa57cb1/first-real-world-data-for-leqembi-reveals-implementation-challenges-in-alzheimer-s-treatment 2025-04-07T09:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/573066723cd670cd/gsk-expands-neurodegenerative-disease-portfolio-with-2-5b-abl-bio-partnership 2025-04-07T08:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/f85c2e10de1299c5/sun-pharma-launches-fexuclue-in-india-a-novel-treatment-for-erosive-esophagitis 2025-04-07T08:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/85a915fc949e2544/proteomics-international-s-blood-test-achieves-91-4-accuracy-in-detecting-oesophageal-cancer 2025-04-07T07:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/74bb155ae69f4fbe/neurelis-to-present-new-data-on-diazepam-nasal-spray-for-seizure-management-at-aan-annual-meeting 2025-04-07T05:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6d08cc9b5b4658c/specialty-pharmacists-drive-significant-improvements-in-non-ms-neurology-care-study-shows 2025-04-07T03:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/9fbfbf75d5d7ca79/gsk-and-abl-bio-partner-on-ps2-billion-deal-to-overcome-blood-brain-barrier-in-neurodegenerative-disease-treatment 2025-04-07T02:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/cd7afb6395aa2063/nih-launches-first-clinical-trial-of-moderna-s-mrna-vaccine-against-deadly-nipah-virus 2025-04-07T01:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/a7a6df9632ac7c35/fda-approved-insomnia-drug-suvorexant-shows-promise-in-reducing-alzheimer-s-related-proteins 2025-04-07T01:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/0e8b46329451c263/luye-pharma-launches-erzofri-single-dose-initiation-long-acting-injectable-for-schizophrenia-treatment 2025-04-06T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/ecfef13593ec081d/china-advances-rice-derived-human-serum-albumin-to-new-drug-approval-stage 2025-04-06T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/ee67184c86f2104b/once-nightly-sodium-oxybate-shows-safety-profile-in-narcolepsy-patients-with-sleep-apnea-concerns 2025-04-06T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/f79ab1d0e134a695/climate-change-and-neurological-health-expert-highlights-critical-connections-and-action-steps 2025-04-06T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/cf7357442fc23478/novel-therapies-show-promise-for-chronic-spontaneous-urticaria-with-complete-response-rates-exceeding-30 2025-04-06T02:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/0a6cdb609e811db4/gene-editing-breakthrough-david-liu-s-base-and-prime-editing-technologies-transform-treatment-of-genetic-diseases 2025-04-06T01:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/8cb0d37defb7e8f3/canadian-scientist-dr-daniel-drucker-wins-breakthrough-prize-for-glp-1-hormone-discovery-behind-ozempic-and-mounjaro 2025-04-06T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/5da9c82bb7393e0d/epilepsy-drug-ezogabine-shows-promise-as-novel-depression-treatment-by-targeting-brain-potassium-channels 2025-04-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1117f153eaef15a8/arizona-advances-bill-for-10m-ibogaine-clinical-trials-to-treat-ptsd-and-neurological-disorders 2025-04-05T23:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/b688d25527756767/incog-biopharma-services-announces-major-facility-and-capacity-expansion-for-2025 2025-04-05T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/10a72897c3e6eb74/bioskryb-genomics-forms-strategic-partnerships-to-revolutionize-single-cell-multi-omics-analysis 2025-04-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d15871db3afb07a0/aptevo-therapeutics-secures-2-1-million-in-financing-to-advance-immune-oncology-pipeline 2025-04-05T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/fcacde3ffe0a823b/next-generation-gene-therapies-evolving-beyond-viral-vectors-towards-more-affordable-sustainable-solutions 2025-04-05T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/4a770e7016bbbca3/study-finds-no-benefit-in-pausing-btk-inhibitors-during-covid-19-vaccination-for-cll-patients 2025-04-05T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/0654f686d683b9b8/statins-show-promise-in-slowing-alzheimer-s-cognitive-decline-large-scale-studies-suggest 2025-04-05T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ed5f5ddf55d6dea/supreme-court-questions-roche-on-high-pricing-of-sma-drug-risdiplam-in-india 2025-04-05T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4146ce5978deab4/eu-approves-aurobindo-pharma-s-dyrupeg-new-pegfilgrastim-biosimilar-for-chemotherapy-patients 2025-04-05T10:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/bf70c248f9aec1b7/fda-issues-complete-response-letter-for-milestone-pharmaceuticals-etripamil-nasal-spray 2025-04-05T07:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/30bdad1ddea21298/precision-medicine-in-alzheimer-s-disease-mayo-clinic-expert-outlines-future-of-targeted-treatments 2025-04-05T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/d3fd04dc9dbb0baa/trump-administration-halts-medicare-and-medicaid-coverage-for-anti-obesity-medications 2025-04-05T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/6d389027a8e51266/antag-therapeutics-launches-first-in-human-trial-of-novel-gipr-antagonist-for-obesity-treatment 2025-04-05T02:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/8ed081adc113cba1/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-new-chief-medical-officer 2025-04-05T02:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/0cd87c14e20a52c4/cancer-drug-use-rapidly-declines-following-withdrawal-of-fda-accelerated-approval 2025-04-05T01:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/e0c62030e9b661d4/fda-rejects-drug-studies-due-to-data-falsification-by-indian-cro-raptim-research 2025-04-05T01:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/fa692faceace2c30/neurosense-to-present-promising-phase-2b-data-for-novel-als-drug-primec-at-aan-meeting 2025-04-04T22:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/73ca056d60d8d0bb/fda-workforce-reduction-creates-new-challenges-for-drug-development-programs 2025-04-04T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/dfd84e0fce17d05f/fda-grants-rare-pediatric-disease-designation-to-neo100-for-aggressive-childhood-brain-cancer 2025-04-04T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/b1e21a47acbe0555/tr1x-secures-8-million-cirm-grant-to-advance-novel-cell-therapy-for-graft-versus-host-disease 2025-04-04T19:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/acfb0ef2dd834caf/arvinas-arv-102-shows-promising-brain-penetration-and-lrrk2-reduction-in-first-in-human-parkinson-s-trial 2025-04-04T19:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/adcfd1b893c87abe/novel-nk-cell-therapy-with-bispecific-antibody-shows-93-response-rate-in-refractory-lymphoma 2025-04-04T19:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/a14e427d222d4412/sanofi-licenses-nurix-s-novel-transcription-factor-program-for-autoimmune-disease-treatment 2025-04-04T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/news/53caeb9778dc2171/tremfya-becomes-first-il-23-inhibitor-to-reduce-structural-damage-in-psoriatic-arthritis 2025-04-04T16:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/15f195ffc8a01c06/sanofi-and-cathay-capital-launch-275m-fund-for-clinical-stage-drug-innovation-in-china 2025-04-04T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/83f2faa1c3f36f5b/former-acting-fda-commissioner-delayed-novavax-vaccine-approval-raising-regulatory-concerns 2025-04-04T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/467916d02408988a/avita-medical-launches-cohealyx-new-collagen-based-dermal-matrix-accelerates-wound-healing 2025-04-04T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/521de2a3945e7b85/gland-pharma-secures-usfda-approval-for-acetaminophen-injection-for-pain-management 2025-04-04T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/4cae261e18184bee/orthocell-secures-fda-clearance-for-remplir-nerve-repair-device-targeting-1-6-billion-us-market 2025-04-04T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/e554b5848c78cf69/astrazeneca-secures-eu-approval-for-datroway-in-breast-cancer-treatment 2025-04-04T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/a89e029639206160/vividion-therapeutics-initiates-phase-i-trial-of-novel-ras-pi3ka-inhibitor-for-advanced-solid-tumors 2025-04-04T11:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/47b46a3a65340d1b/uk-launches-first-anti-viral-drug-trial-for-long-covid-treatment 2025-04-04T10:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/5fde85089b2bc274/pacira-biosciences-advances-novel-gene-therapy-for-knee-osteoarthritis-with-first-patient-dosed-in-phase-2-trial 2025-04-04T10:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/5e545f7254a7ed5d/accustem-s-msc-blood-test-set-to-transform-lung-cancer-screening-in-the-us 2025-04-04T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee2b0708867f5c1d/novo-nordisk-launches-novocare-r-pharmacy-offering-authentic-wegovy-r-at-499-monthly 2025-04-04T03:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/c44adba8bcfd454b/patient-reported-physical-function-predicts-daratumumab-efficacy-in-multiple-myeloma-patients 2025-04-04T02:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/8ec3ce0ecc0b0a3c/new-six-month-bpalm-regimen-shows-promise-for-drug-resistant-tb-patients-in-india 2025-04-04T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/435d9ad3f980de5d/phase-i-trial-demonstrates-safety-of-targeted-therapy-for-deadly-childhood-brain-tumor-dipg 2025-04-04T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/140782125a2b902f/nih-backed-ai-tool-reduces-hospital-readmissions-for-opioid-use-disorder-by-47 2025-04-04T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/1ad4d4d0eefe4ca3/aiml-secures-2-17-million-in-oversubscribed-private-placement-for-ai-healthcare-innovations 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b13c0121d440b19e/3d-cell-culture-market-set-to-reach-3-48-billion-by-2028-as-pharma-industry-embraces-advanced-in-vitro-models 2025-04-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/353784291caf367b/chinese-biotech-firms-surge-in-global-oncology-licensing-deals-commanding-30-billion-in-2024 2025-04-03T23:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f176965b0b0bb27/siemens-acquires-dotmatics-for-5-1-billion-to-enhance-ai-capabilities-in-life-sciences 2025-04-03T22:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/b6583c6728e4162e/edgewise-therapeutics-faces-regulatory-and-safety-setbacks-across-multiple-drug-programs 2025-04-03T22:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/69186d3045b2f862/uplizna-becomes-first-fda-approved-treatment-for-igg4-related-disease-reducing-flare-risk-by-87 2025-04-03T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/64b9ddf610c4d255/groundbreaking-histotripsy-cancer-treatment-trials-to-begin-in-singapore-by-2025 2025-04-03T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/03d3c081a6c45fc7/brca2-mechanism-reveals-why-parp-inhibitors-work-in-only-some-cancer-patients 2025-04-03T20:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/16f6d17c8dc61bdf/beigene-discontinues-tigit-inhibitor-ociperlimab-after-phase-iii-trial-failure-prediction 2025-04-03T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/03b154008ca157dc/pharmamar-expands-global-reach-of-zepzelca-with-argentina-approval-and-merck-partnership-for-japan 2025-04-03T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/03ee4ce2243fabeb/onesource-specialty-pharma-positions-for-major-growth-as-semaglutide-patent-expires-in-2026 2025-04-03T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/580ef2ef21a2acd7/domain-therapeutics-to-showcase-novel-gpcr-targeting-oncology-programs-at-aacr-2025 2025-04-03T17:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/dea75e239a0d23db/buntanetap-shows-promise-for-parkinson-s-patients-with-mild-dementia-in-phase-iii-trial 2025-04-03T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/67736f01e49e9b9a/fda-clears-minovia-s-ind-for-phase-ii-trial-of-novel-mitochondrial-therapy-in-fatal-pediatric-disease 2025-04-03T16:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/7a0f3dc44d98d60c/ku-cancer-center-and-va-partnership-expands-early-phase-clinical-trial-access-for-veterans 2025-04-03T16:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/88178139e0e40e8e/blossomhill-therapeutics-to-present-novel-omni-egfr-inhibitor-bh-30643-at-aacr-2025-for-nsclc-treatment 2025-04-03T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/c2769649c3d94ec8/virtual-reality-shows-promise-as-non-opioid-pain-management-for-cancer-patients 2025-04-03T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/fd92bc8616d65531/plex-research-and-ginkgo-bioworks-partner-to-accelerate-drug-repurposing-through-ai-powered-analysis 2025-04-03T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/8bbdde7af9febdf8/variant-secures-ema-endorsement-for-var002-gene-therapy-targeting-inherited-retinal-dystrophies 2025-04-03T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/dc482aa039a45f50/meitheal-pharmaceuticals-launches-generic-liraglutide-amid-ongoing-victoza-shortage 2025-04-03T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/c5298f04d54bc402/alembic-pharmaceuticals-receives-fda-approval-for-pantoprazole-sodium-injection-to-treat-gerd 2025-04-03T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/aea7a9a318a8a5c5/lilly-licenses-sangamo-s-blood-brain-barrier-capsid-technology-in-1-4b-cns-deal 2025-04-03T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6419fd91d8fa71d0/beigene-discontinues-ociperlimab-development-after-failed-phase-iii-lung-cancer-trial 2025-04-03T14:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/c5ecb1a273e34313/lumen-bioscience-s-oral-biologic-lmn-201-achieves-100-clinical-cure-rate-for-c-difficile-infection-in-preliminary-trial 2025-04-03T13:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/9bc7adc7c1b59246/brain-implant-breakthrough-enables-real-time-speech-for-stroke-survivor-after-18-years 2025-04-03T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/626a37043015cec6/sarepta-and-roche-temporarily-halt-elevidys-trials-in-europe-following-patient-death 2025-04-03T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/7ee05b5a001bb971/roche-advances-parkinson-s-disease-research-with-novel-assessment-methods-and-digital-health-technologies 2025-04-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/18fbc88ae739eedc/novel-gene-expression-signature-predicts-immunotherapy-response-across-cancer-types 2025-04-03T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/9273dc592882e0c2/vizgen-settles-litigation-with-10x-genomics-and-harvard-secures-future-for-merfish-technology 2025-04-03T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e322af058a5204fd/novo-holdings-makes-landmark-investment-in-fungal-biotech-leader-sylvan-to-accelerate-sustainable-solutions 2025-04-03T11:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/80aa8ed403d5ab82/concentra-biosciences-to-acquire-allakos-for-0-33-per-share-in-strategic-biotech-deal 2025-04-03T11:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/7e8cb115021a2b31/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-two-rare-diseases 2025-04-03T10:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/ec5c35fac1162587/fda-grants-orphan-drug-designation-to-resvita-bio-s-rvb-003-for-netherton-syndrome 2025-04-03T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/dbeae4095f96505a/linusbio-and-autism-speaks-join-forces-to-accelerate-early-autism-diagnosis-through-hair-biomarker-test 2025-04-03T08:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/59b633d45e436ddb/immucell-initiates-investigational-use-of-re-tain-for-subclinical-mastitis-in-dairy-cows 2025-04-03T07:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/ba7b3ab0cb8a4f5c/fda-clears-groundbreaking-ai-surgical-guidance-platforms-from-proprio-and-medivis 2025-04-03T07:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/b5c1644d8f932976/resmed-launches-nightowl-fda-cleared-home-sleep-apnea-test-now-available-across-us 2025-04-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0a6d39a52c1591b8/akamis-bio-initiates-phase-1b-fortress-trial-of-ng-350a-for-locally-advanced-rectal-cancer 2025-04-03T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/57f56f8fa7ded1e4/pbm-reform-and-340b-program-changes-lead-federal-healthcare-policy-agenda 2025-04-03T02:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/22184bac49152afe/edgewise-s-edg-7500-shows-promise-in-phase-2-hcm-trial-with-improved-safety-profile 2025-04-03T02:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/3458b8f074390920/lift-biosciences-advances-first-in-class-neutrophil-therapy-toward-clinical-trials-with-strategic-partnerships 2025-04-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7161fada870c90c9/fda-uncovers-significant-data-integrity-issues-at-indian-contract-research-organization 2025-04-03T01:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/bb4b2a470da3ce60/healthcare-affordability-crisis-deepens-35-of-americans-unable-to-access-quality-care 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0304d03ebcfbe262/endoziptm-automated-endoscopic-system-shows-11-4-weight-loss-and-improved-comorbidities-in-obesity-trial 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c50e660fa80bd94d/gene-deletion-strategy-shows-promise-for-treating-short-bowel-syndrome 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/67c710610baaea52/novel-dna-aptamers-deliver-dual-action-therapy-against-leukemia-stem-cells 2025-04-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b76b799fb5906506/uspto-implements-bifurcated-patent-review-process-creating-new-hurdles-for-challengers 2025-04-02T23:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb06cae1d5fb6c71/federal-court-upholds-fda-approval-of-elanco-s-ammonia-reducing-cattle-drug-experior 2025-04-02T22:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/f3df6ea5158945c4/roche-s-high-dose-ocrevus-fails-phase-3-trial-for-multiple-sclerosis-boosting-tg-therapeutics 2025-04-02T20:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/3e38628119105dea/mesoblast-s-ryoncil-receives-us-fda-orphan-drug-approval-driving-15-share-price-surge 2025-04-02T20:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/241763ecf9145e07/patient-organizations-emerge-as-critical-partners-in-drug-development-and-clinical-research 2025-04-02T20:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/0bb72ab04f1c0e33/fda-clears-native-orthopaedics-dragonfly-technology-for-meniscal-root-repair 2025-04-02T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ef0d0976d2b6b8b/fda-misses-deadline-for-full-approval-decision-on-novavax-s-covid-19-vaccine 2025-04-02T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/a063aee5283cd2c0/first-patient-dosed-in-pioneering-zolar-trial-of-tlx300-cdx-for-advanced-soft-tissue-sarcoma 2025-04-02T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/6e71f7a3bde42bbe/roche-s-ocrevus-shows-strong-efficacy-in-musette-phase-iii-trial-for-multiple-sclerosis 2025-04-02T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/972f0d088d137c4b/fda-shows-greater-regulatory-flexibility-for-first-in-class-drugs-compared-to-ema-study-reveals 2025-04-02T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/4248699e03c8337c/supreme-court-upholds-fda-s-authority-to-deny-flavored-vaping-products 2025-04-02T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/1c52ee67bf812d0d/africa-launches-continental-medicine-approval-system-with-first-five-products 2025-04-02T19:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/33eb03b02ec5fbe1/biomarin-s-palynziq-shows-promising-results-in-adolescents-with-pku-setting-stage-for-label-expansion 2025-04-02T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/1ebde0f22478c6d4/atsena-therapeutics-secures-150m-series-c-funding-to-advance-ocular-gene-therapies-for-inherited-blindness 2025-04-02T17:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/88a5da63fa5af276/vopemed-secures-2-29m-pre-seed-funding-to-advance-ai-powered-surgical-visualization-technology 2025-04-02T17:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/cb81b1f4bf1e9ccd/european-commission-grants-orphan-designation-to-pharvaris-deucrictibant-for-bradykinin-mediated-angioedema 2025-04-02T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/73e11f6f75b822c1/hoth-therapeutics-strengthens-intellectual-property-portfolio-with-new-patent-filings-for-ht-001-and-ht-kit 2025-04-02T16:42:36+00:00 hourly 0.9 https://trial.medpath.com/news/b5fd2b895926e0c2/roche-s-phase-iii-musette-trial-confirms-current-ocrevus-dose-optimal-for-multiple-sclerosis 2025-04-02T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/483b5eb2a79ea80e/oncozenge-bolsters-phase-3-team-for-bupizengetm-as-company-prepares-for-pivotal-trial-in-oral-mucositis 2025-04-02T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/ac508438b4061c4c/kyowa-kirin-and-la-jolla-institute-extend-35-year-research-alliance-with-focus-on-cell-and-gene-therapies 2025-04-02T16:39:31+00:00 hourly 0.9 https://trial.medpath.com/news/3f24c161e160b273/hoth-therapeutics-ht-alz-shows-promising-dual-action-against-alzheimer-s-in-preclinical-study 2025-04-02T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/7b4121e685a37cd1/nulibry-shows-significant-survival-benefits-in-ultra-rare-mocd-type-a-landmark-clinical-evidence-published 2025-04-02T16:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/33578813556e6a1f/sunshine-biopharma-s-mrna-therapy-shows-promise-in-liver-cancer-treatment 2025-04-02T16:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/9a200f308f1ac9a1/mount-sinai-launches-ai-powered-center-to-revolutionize-small-molecule-drug-discovery 2025-04-02T16:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/b092c2574a7f2d7f/real-world-studies-confirm-bevacizumab-biosimilars-deliver-cost-savings-and-equivalent-clinical-outcomes-in-metastatic-colorectal-cancer 2025-04-02T16:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/70c263fbb3ff3c25/fda-approves-revvity-s-automated-latent-tuberculosis-test-enhancing-diagnostic-efficiency 2025-04-02T16:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/aef77d26f4451818/eisai-launches-japan-s-first-over-the-counter-proton-pump-inhibitor-pariet-s 2025-04-02T15:38:04+00:00 hourly 0.9 https://trial.medpath.com/news/2086154ba3769c24/artis-biosolutions-launches-with-landmark-bio-acquisition-to-transform-advanced-therapy-manufacturing 2025-04-02T14:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/198c79699523d96b/withings-bpm-vision-blood-pressure-monitor-receives-fda-clearance-and-launches-in-us-market 2025-04-02T14:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/f551e54b4e900c2a/helsinn-submits-new-akynzeo-r-formulation-to-ema-for-chemotherapy-induced-nausea-and-vomiting 2025-04-02T14:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/cde849a0697464e0/silmitasertib-shows-promise-in-advanced-basal-cell-carcinoma-patients-with-no-treatment-options 2025-04-02T13:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/0e6d43eda8b38113/ac-immune-s-parkinson-s-immunotherapy-shows-promising-results-in-phase-2-trial 2025-04-02T13:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/f3b1c5847280f7b3/multiomic-health-and-alloy-therapeutics-partner-to-develop-precision-kidney-medicines-using-ai 2025-04-02T13:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/15e44f2fc3899801/hanmi-s-gugutams-launches-in-mexico-as-aditams-first-dual-opg-ed-combination-therapy-enters-latin-american-market 2025-04-02T13:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/1d52829ba2106794/jointmedica-launches-ide-study-for-novel-polymotion-r-hip-resurfacing-system 2025-04-02T13:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/5f41e2287a23ad68/asia-pacific-leads-global-surge-in-infectious-disease-clinical-trials-with-70-growth-rate 2025-04-02T13:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/96c48a0d024f72b9/new-antibiotic-class-discovered-in-soil-sample-could-combat-drug-resistant-bacteria 2025-04-02T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/41cedfdb05bd4bf6/accord-healthcare-secures-positive-chmp-opinion-for-denosumab-biosimilars-targeting-osteoporosis-and-oncology 2025-04-02T10:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/964a15d7608f600d/first-vista-inhibitor-expected-to-receive-fda-approval-by-2028-according-to-new-research 2025-04-02T10:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/80bef5865ef1415e/fda-clears-first-wireless-catheter-free-urodynamics-system-for-bladder-dysfunction-testing 2025-04-02T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/549cde02c6c9db54/boehringer-ingelheim-prepares-for-multiple-new-product-launches-in-2025-following-strong-r-d-investment 2025-04-02T04:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/b319de7b3168d328/jynneos-vaccine-shows-reduced-efficacy-against-mpox-in-hiv-patients-study-reveals 2025-04-02T04:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/be7444ee5bc53cf6/oculis-expands-privosegtor-development-to-naion-and-multiple-sclerosis-following-positive-phase-2-results 2025-04-02T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/626a3503f689d45c/scientific-industries-launches-dots-mps-for-cell-culture-biopharma-market-reports-24-bioprocessing-revenue-growth 2025-04-02T03:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/2ed746ccbc6fbde8/phase-1-trial-shows-promise-for-novel-intraperitoneal-therapy-in-peritoneal-metastases 2025-04-02T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/01bbdb435b03517d/federal-court-overturns-fda-s-laboratory-developed-test-regulation-in-major-win-for-diagnostic-industry 2025-04-02T01:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/c62179e518b7407e/mayo-clinic-launches-groundbreaking-study-on-rapidly-progressive-alzheimer-s-disease 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8562bd091aacb86b/jabez-biosciences-advances-novel-dhodh-inhibitor-jbz-001-in-phase-1-oncology-trial 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/970e56dbecd8970b/japan-prioritizes-14-drug-loss-products-for-urgent-domestic-development-to-address-critical-medical-needs 2025-04-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/02f77b5a63e548e0/merck-opts-in-for-global-license-of-abbisko-s-pimicotinib-for-85m 2025-04-01T22:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/3897b27a903cbd04/ynvisible-partners-with-ccl-design-to-scale-production-of-ultra-low-power-e-paper-displays 2025-04-01T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/994f3d6255e2c4be/glucotrack-advances-to-clinical-stage-with-innovative-implantable-continuous-blood-glucose-monitor 2025-04-01T19:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/9d0f03ca171c03b1/nih-terminates-funding-for-vaccine-hesitancy-research-amid-rising-disease-outbreaks 2025-04-01T19:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/23189e8ddf018324/entvin-ai-secures-500k-from-y-combinator-to-transform-fda-drug-approval-process 2025-04-01T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/3a58943e5678d314/cvac-system-demonstrates-superior-stone-clearance-in-multiple-real-world-studies-at-aua-2025 2025-04-01T18:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/3f4386cd492f946f/d-wave-and-japan-tobacco-pioneer-quantum-enhanced-ai-for-drug-discovery 2025-04-01T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a48113e8247e947/alzheon-s-valiltramiprosate-shows-promising-results-for-early-stage-alzheimer-s-in-apoe4-homozygotes 2025-04-01T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/de60ab9bce0a34b9/ema-proposes-streamlined-approval-process-for-biosimilars-to-enhance-patient-access 2025-04-01T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/8c9ef035bc05a55e/zeiss-medical-technology-s-ilm-blue-receives-nmpa-approval-in-china-expanding-surgical-options-for-retinal-surgeons 2025-04-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/fe96e17047b28c09/fda-approves-yingli-pharma-s-phase-iii-trial-for-novel-ptcl-treatment-linperlisib 2025-04-01T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/026e8ce7a2895e95/fda-approves-freeze-dried-jynneos-vaccine-for-mpox-and-smallpox-prevention 2025-04-01T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/b1b841dd9553f972/amneal-launches-boruzu-first-ready-to-use-bortezomib-injection-for-multiple-myeloma-treatment 2025-04-01T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/0039f564e657503c/selected-til-therapy-combined-with-pembrolizumab-shows-promising-results-for-metastatic-gastrointestinal-cancers 2025-04-01T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/0b1ebd615b538ed7/avalyn-s-inhaled-nintedanib-shows-promising-safety-profile-in-phase-1-trials-for-ipf-treatment 2025-04-01T16:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/cfd9183c856e4067/sernova-s-cell-pouch-bio-hybrid-organ-shows-promise-in-type-1-diabetes-clinical-trial 2025-04-01T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/b2e76dd0380b0f25/kazia-therapeutics-sells-cantrixil-intellectual-property-rights-to-vivesto-for-1-million 2025-04-01T14:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/bb4dcc78f1052623/vaxcyte-s-vax-24-shows-promising-results-despite-phase-2-serotype-misses-in-infant-study 2025-04-01T13:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/1c0defee4614c3b9/esteve-acquires-global-rights-to-increlex-for-rare-growth-disorder-treatment 2025-04-01T13:38:32+00:00 hourly 0.9 https://trial.medpath.com/news/7ec435101e695ab3/inmune-bio-reveals-promising-demographics-in-mindful-phase-ii-alzheimer-s-trial 2025-04-01T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/c4ee4baf02901a2c/cerevance-s-solengepras-fails-primary-endpoint-in-phase-ii-parkinson-s-trial-shows-promise-for-non-motor-symptoms 2025-04-01T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/0158ed4d36ba9cbb/navigo-proteins-and-sck-cen-partner-to-advance-terbium-161-based-radiotheranostics 2025-04-01T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/8f35fb6b5ce9f5a9/akums-launches-first-in-india-ripasudil-timolol-combination-eye-drops-for-glaucoma-treatment 2025-04-01T13:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/cd55b3a74af1d613/mepsgen-launches-nanocaliburtm-in-us-advanced-microfluidic-platform-for-scalable-nanoparticle-production 2025-04-01T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/add6ee17dbc71ee6/quantum-biopharma-advances-novel-pet-imaging-biomarker-for-multiple-sclerosis-with-first-patient-scan 2025-04-01T13:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/d27df1ba196cc052/proofpilot-and-inspire-form-strategic-partnership-to-enhance-clinical-trial-recruitment 2025-04-01T13:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/21d29f0901dfce6c/spanios-forms-strategic-partnerships-to-accelerate-cancer-drug-development-using-organoid-technology 2025-04-01T11:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/0574c20a02239cf1/ucb-showcases-promising-neurodegenerative-disease-research-at-ad-pd-2025 2025-04-01T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/f8d0ee6f3570d7ca/glenmark-pharmaceuticals-launches-generic-vancomycin-hydrochloride-injection-in-us-market 2025-04-01T07:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/f044265992602be0/zimmer-biomet-s-ribfix-advantage-system-receives-first-ce-mark-for-intrathoracic-rib-fixation 2025-04-01T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0cda4a3677537f95/newron-pharmaceuticals-advances-pivotal-phase-iii-program-for-treatment-resistant-schizophrenia 2025-04-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/47defed1939c2fb8/psyence-biomed-accelerates-phase-iib-psilocybin-trial-for-adjustment-disorder-in-cancer-patients 2025-04-01T03:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/a3fc3089869e3a16/cell-and-gene-therapy-sector-overcomes-manufacturing-and-investment-hurdles-amid-30-funding-growth 2025-04-01T02:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/c0c33f81e8fc0ecd/meta-analysis-confirms-trastuzumab-deruxtecan-efficacy-in-her2-positive-gastrointestinal-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8896ca62e77bf65/tirzepatide-shows-significant-kidney-function-improvement-in-patients-with-obesity-and-heart-failure 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fb96ad0300f7f8f/bd-launches-revolutionary-facsdiscover-a8-cell-analyzer-with-dual-breakthrough-technologies 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c84af85f6f12cd29/astrazeneca-launches-phase-iii-trials-testing-novel-immunotherapy-rilvegostomig-in-lung-and-breast-cancers 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ff83784f875a138/regulators-adapt-to-ai-revolution-in-healthcare-mhra-leads-with-new-guidance-and-sandbox-initiative 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/80ac7e2de448a5d2/dizal-to-present-novel-cancer-therapies-dzd8586-and-dzd6008-at-asco-2025 2025-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3a8a5dd7143ef87/keros-therapeutics-reports-positive-phase-1-results-for-ker-065-in-duchenne-muscular-dystrophy-program 2025-03-31T22:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/fa1b275595aeb3e5/fda-s-cell-and-gene-therapy-champion-peter-marks-departs-leaving-industry-at-critical-juncture 2025-03-31T22:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/8b12d46f74e99aae/rademikibart-shows-unprecedented-420ml-lung-function-improvement-in-phase-2-asthma-trial 2025-03-31T22:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/1aaed0aaf56a1760/fortress-biotech-reports-strong-2024-results-with-two-fda-approvals-and-strategic-acquisition-deal 2025-03-31T22:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/21541908b078942a/fda-approves-bavarian-nordic-s-freeze-dried-jynneos-vaccine-for-smallpox-and-mpox-prevention 2025-03-31T22:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/1b2f8c5ffdf88d24/ascendis-pharma-submits-nda-for-novel-achondroplasia-treatment-with-multiple-clinical-benefits 2025-03-31T22:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/f631d5726dd4e051/chemotherapy-plus-local-excision-shows-promise-for-node-negative-low-rectal-cancer-patients 2025-03-31T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/bce5ab762aa4dd46/abec-launches-advanced-therapy-bioreactor-to-transform-cell-therapy-manufacturing 2025-03-31T19:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/e089e28e06b4a8a2/cosmos-trial-cocoa-extract-shows-no-significant-long-term-benefits-for-age-related-macular-degeneration 2025-03-31T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/6133ab4ec3a7de04/mitsubishi-tanabe-pharma-america-to-present-breakthrough-neurodegenerative-disease-research-at-aan-2025 2025-03-31T16:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/733ea04f9ea237b7/genomoncology-and-chronetyx-laboratories-partner-to-accelerate-cancer-treatment-through-advanced-genomic-testing 2025-03-31T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/fcb1971a67efc9d5/groundbreaking-study-surgery-may-be-unnecessary-for-early-stage-breast-cancer-patients 2025-03-31T16:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/60dcedab302d7739/promising-pipeline-for-soft-tissue-sarcoma-treatment-expands-with-130-therapies-in-development 2025-03-31T16:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/b9ccfd261f5c08e8/ema-confirms-mysimba-s-cardiovascular-safety-for-one-year-use-in-weight-management 2025-03-31T16:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/671a1344570b07cc/japan-approves-luye-pharma-s-twice-weekly-rivastigmine-patch-for-alzheimer-s-disease 2025-03-31T16:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/12c1041cb3009ff6/positron-corporation-secures-8-million-investment-to-expand-pet-ct-imaging-technology 2025-03-31T15:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/d13494f28f958a1e/fda-grants-breakthrough-therapy-designation-to-ideaya-s-darovasertib-for-neoadjuvant-uveal-melanoma 2025-03-31T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/bc5cfc110ae6ff6f/isomorphic-labs-secures-600-million-to-advance-ai-powered-drug-discovery-platform 2025-03-31T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/b7082f311bf63d66/vanda-pharmaceuticals-submits-nda-for-novel-antipsychotic-bysanti-to-treat-bipolar-i-disorder-and-schizophrenia 2025-03-31T13:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/0576fcf7c3d845c3/fda-clears-expedited-pathway-for-tharimmune-s-th104-opioid-defense-drug-without-additional-clinical-trials 2025-03-31T13:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/97b7b5d5a1c65477/lundbeck-expands-proceed-trial-to-include-intravenous-administration-of-novel-anti-pacap-antibody-for-migraine-prevention 2025-03-31T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/420f3e210ac70357/hybrid-closed-loop-systems-show-significant-glycemic-benefits-for-pregnant-women-with-type-1-diabetes 2025-03-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a02d4d3b49b2af4/abbott-s-triclip-shows-sustained-benefits-for-tricuspid-regurgitation-patients-in-two-year-study 2025-03-31T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/8585c5b0aded1372/eagle-pharmaceuticals-secures-69-million-deal-to-monetize-bendeka-royalties 2025-03-31T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0f139cb684fd36f/maat-pharma-s-maat034-shows-promise-in-enhancing-immunotherapy-response-for-cancer-treatment 2025-03-31T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/05dd6ae31d57a300/fda-leadership-shakeup-peter-marks-forced-resignation-sends-shockwaves-through-biopharma-industry 2025-03-31T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/648d682d85f60fc0/cadrenal-therapeutics-advances-towards-phase-3-trial-of-tecarfarin-for-lvad-patients 2025-03-31T10:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/3594f4bf9e3e049d/geopolitical-shifts-and-industry-expansion-navigating-the-future-of-cell-and-gene-therapy-in-2025 2025-03-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a9d478134b2b2de/marker-therapeutics-mt-601-shows-78-response-rate-in-refractory-lymphoma-patients 2025-03-31T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd51d121e5fdc950/biotest-reports-6-sales-growth-in-2024-fda-approves-yimmugo-for-us-market 2025-03-31T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/62543ce8a1586327/radiopharmaceuticals-the-next-frontier-in-precision-oncology-as-big-pharma-competes-for-market-share 2025-03-31T07:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/5e33500ba2e2c848/nmpa-approves-gyre-therapeutics-clinical-trial-for-pirfenidone-in-oncology-related-lung-complications 2025-03-31T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0a9aa6630d9bace2/has-healthcare-advanced-synthesis-sa-acquires-cerbios-pharma-sa-to-create-leading-international-group-in-the-cdmo-sector-backed-by-65-equity-partners 2025-03-31T06:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/f545e5251a176604/nls-pharmaceutics-secures-28-million-in-financing-to-advance-merger-with-kadimastem-and-cell-therapy-pipeline 2025-03-31T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/f130010194968c3e/novotech-secures-major-investment-from-gic-temasek-and-tpg-to-expand-global-cro-operations 2025-03-31T05:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/e5d62bd39cb086fc/novel-bcma-directed-car-t-cell-therapy-shows-promising-efficacy-in-relapsed-refractory-multiple-myeloma-and-al-amyloidosis 2025-03-31T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/935193ca8e7d505f/otsuka-submits-bla-for-sibeprenlimab-a-novel-targeted-therapy-for-iga-nephropathy 2025-03-31T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/62c306c1cd0d91b8/reach3-trial-update-ruxolitinib-shows-promising-efficacy-in-steroid-refractory-chronic-gvhd 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/171a773adcd69d50/trethera-reports-disease-stabilization-in-late-stage-als-patient-treated-with-tre-515 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e4857e8a132dd03/crispr-gene-editing-advances-from-laboratory-to-clinic-with-250-active-trials-across-multiple-therapeutic-areas 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/01e2f2583c201301/bioversys-secures-critical-chinese-patent-for-bv100-advancing-treatment-for-deadly-antibiotic-resistant-infections 2025-03-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da86e5e6d5876d22/bhf-protect-tavi-trial-fails-to-show-benefit-of-cerebral-embolic-protection-during-tavi 2025-03-30T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/47fdfce18b1f8702/reviva-to-present-long-term-phase-3-data-for-brilaroxazine-in-schizophrenia-at-sirs-congress 2025-03-30T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/5390444e082952ef/score-study-semaglutide-2-4-mg-shows-57-reduction-in-cardiovascular-events-in-real-world-analysis 2025-03-30T17:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/e3e393068d9cd862/fresh-up-trial-challenges-fluid-restriction-guidelines-in-chronic-heart-failure-patients 2025-03-30T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/9814634819f0d451/medtronic-s-evolut-tavr-system-demonstrates-superior-durability-and-performance-at-five-year-mark 2025-03-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/696998e3404ea4e3/brii-bio-s-brii-179-shows-promise-in-identifying-responders-for-hbv-functional-cure 2025-03-30T13:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/2e8ba7b70bb2db2c/ninerafaxstat-shows-promise-in-phase-2-trial-for-cardiometabolic-hfpef-patients 2025-03-30T13:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/d124ff7eb335ef4b/4f-pcc-demonstrates-superior-efficacy-over-frozen-plasma-in-managing-cardiac-surgery-bleeding 2025-03-30T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/190ff156b5fd1609/study-reveals-chemotherapy-causes-greater-long-term-physical-health-decline-in-breast-cancer-survivors-than-endocrine-therapy 2025-03-30T13:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/8d49907ea0393f36/kitea-health-secures-fda-fast-track-status-and-completes-groundbreaking-pediatric-brain-implant 2025-03-30T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/1b446f6c4a35063d/fremanezumab-demonstrates-long-term-efficacy-in-migraine-prevention-across-multiple-real-world-studies 2025-03-30T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/6e125e9fa138990a/gsk-launches-landmark-study-to-investigate-shingles-vaccine-s-potential-to-reduce-dementia-risk 2025-03-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/46b884df43b7d885/eli-lilly-s-lepodisiran-shows-95-reduction-in-lipoprotein-a-offering-new-hope-for-south-asian-heart-patients 2025-03-29T22:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/caad2289f7618bf3/rakovina-therapeutics-advances-novel-ai-discovered-parp1-and-atr-inhibitors-for-hard-to-treat-cancers 2025-03-29T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/09ebf4a993880473/low-dose-apixaban-proves-effective-and-safer-for-extended-cancer-related-vte-prevention 2025-03-29T20:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/5694c23a7ef4136c/bentracimab-shows-promising-results-in-phase-3-trial-for-reversing-ticagrelor-s-antiplatelet-effects 2025-03-29T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/51d1f8cd380159f8/first-clinical-trial-shows-ai-therapy-bot-effective-for-depression-and-anxiety 2025-03-29T19:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/61d9c94716e11619/novel-drug-lorundrostat-shows-significant-promise-for-uncontrolled-hypertension-in-phase-2b-trial 2025-03-29T19:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/c6210489effd412b/vertex-s-vx-880-cell-therapy-enables-type-1-diabetes-patients-to-achieve-insulin-independence 2025-03-29T17:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/ca3c4599af7c0d41/immune-checkpoint-inhibitors-emerge-as-standard-of-care-for-early-stage-nsclc-new-data-shows 2025-03-29T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/b2be94ca832b0e66/ozempic-significantly-improves-walking-distance-in-patients-with-type-2-diabetes-and-peripheral-artery-disease 2025-03-29T16:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/8241e7e9eb645332/coya-therapeutics-advances-treg-exosome-platform-for-neurodegenerative-disease-treatment 2025-03-29T16:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/f796336490497632/cystic-fibrosis-foundation-invests-2-3-million-in-owlstone-medical-to-develop-breath-based-pathogen-test 2025-03-29T16:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/3c495fa3fba50cab/fda-s-april-decisions-to-shape-future-of-key-therapies-dupixent-opdivo-and-nipocalimab-in-focus 2025-03-29T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/13f928b709d366a2/penetrium-shows-promising-anti-metastatic-effects-in-triple-negative-breast-cancer-preclinical-study 2025-03-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1346f68e0810d00/esa-treatment-shows-survival-benefit-in-lower-risk-myelodysplastic-syndromes 2025-03-29T10:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/69918f7e56e18dae/hhs-announces-major-restructuring-with-10000-job-cuts-raising-concerns-for-healthcare-regulation-and-drug-programs 2025-03-29T07:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/5d067431bfb16cc3/orca-bio-s-phase-iii-precision-t-study-shows-promise-for-novel-t-cell-immunotherapy-in-blood-cancers 2025-03-29T07:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/9399d007c0bbb756/telehealth-evolution-patient-satisfaction-reaches-record-highs-as-virtual-primary-care-transforms-healthcare-access 2025-03-29T02:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/d8d0bb23678986e2/pmi-expands-iqos-heated-tobacco-system-to-fort-lauderdale-following-successful-austin-launch 2025-03-29T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/82f86f1de1cb2d25/fda-approves-roche-s-polivy-as-first-new-frontline-dlbcl-treatment-in-nearly-20-years 2025-03-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f480580c5d28cbb/solaxa-advances-slx-100-to-phase-3-trial-for-rare-spinocerebellar-ataxia-type-27b 2025-03-28T22:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/fa10f7f9bfb916c5/uplizna-shows-remarkable-efficacy-in-reducing-flares-and-glucocorticoid-dependence-in-igg4-related-disease 2025-03-28T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/032573c52565ee09/vertex-halts-vx-264-diabetes-treatment-after-phase-1-2-trial-fails-to-meet-efficacy-endpoint 2025-03-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/2acceb31594f6418/prothena-faces-phase-3-trial-setback-in-neurodegenerative-disease-program 2025-03-28T20:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/756f11031df49d66/ema-recommends-approval-of-averoa-s-xoanacyl-for-chronic-kidney-disease-treatment 2025-03-28T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/bdc93b7723b3213f/labtician-ophthalmics-launches-lab-triactiv-a-novel-triple-action-artificial-tear-for-dry-eye-relief 2025-03-28T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/bf20a9eb745f7a22/fda-expands-pluvicto-approval-for-earlier-treatment-of-metastatic-prostate-cancer 2025-03-28T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/cfca1b31188e3be8/palatin-s-oral-mc1r-agonist-shows-promising-results-in-phase-2-ulcerative-colitis-trial 2025-03-28T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/60920fe68e7bbbab/neonc-technologies-to-list-on-nasdaq-global-market-with-novel-blood-brain-barrier-therapeutics 2025-03-28T16:39:45+00:00 hourly 0.9 https://trial.medpath.com/news/f68b2089eb81e6b2/biontech-s-bnt327-shows-promising-85-response-rate-in-first-line-treatment-for-extensive-stage-sclc 2025-03-28T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/db99e5c8a77a802a/fulzerasib-cetuximab-combination-shows-promise-as-first-line-treatment-for-kras-g12c-mutated-nsclc 2025-03-28T16:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/2341cbb4d7c6f391/triple-combination-acne-gel-shows-efficacy-and-safety-in-hispanic-patients-and-long-term-use 2025-03-28T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/0e485f6b2baa655d/european-commission-withdraws-translarna-s-marketing-authorization-for-duchenne-muscular-dystrophy 2025-03-28T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/5d3fca84288a049d/fda-authorizes-first-at-home-test-for-three-common-stis-expanding-access-to-sexual-health-diagnostics 2025-03-28T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/fd2d70e0aa8d8120/fda-rejects-milestone-s-cardamyst-for-psvt-citing-manufacturing-issues 2025-03-28T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/bf2bcbf7ac5372ab/cd46-targeting-adc-fg-3246-shows-promising-results-in-advanced-prostate-cancer-trial 2025-03-28T16:36:41+00:00 hourly 0.9 https://trial.medpath.com/news/9e63e5b7c4dc2551/traws-pharma-announces-leadership-transition-as-ceo-werner-cautreels-retires 2025-03-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d211539185fc9810/european-regulators-reject-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/46bc6bbfbd9aee5f/european-regulatory-committee-rejects-eli-lilly-s-alzheimer-s-drug-kisunla-over-safety-concerns 2025-03-28T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/5262a445c2a084b3/remegen-s-telitacicept-shows-remarkable-98-response-rate-in-phase-3-trial-for-generalized-myasthenia-gravis 2025-03-28T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/fb61d7b83febfd13/gedeon-richter-submits-tocilizumab-biosimilar-application-to-ema-for-multiple-indications 2025-03-28T10:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/d0b8bf9c66797195/fda-approves-vasorum-s-celt-acd-plus-vascular-closure-device-with-blood-signal-technology 2025-03-28T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/b1a50c070798d6ab/first-human-transplant-of-sperm-producing-stem-cells-offers-hope-for-childhood-cancer-survivors 2025-03-28T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/17e9ed29b0f0ef97/oncozenge-and-molteni-farmaceutici-partner-for-bupizenge-commercialization-in-europe 2025-03-28T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa2873e7eb7749d0/corbus-pharmaceuticals-initiates-phase-1-trial-of-peripherally-restricted-cb1-inverse-agonist-for-obesity 2025-03-28T07:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f0fcd8df8b4148e/merlin-cp-gep-test-shows-breakthrough-results-in-melanoma-risk-assessment-and-treatment-planning 2025-03-28T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7dfe5c11d6886d7/northwestern-medicine-launches-landmark-study-using-apple-watch-to-revolutionize-afib-treatment 2025-03-28T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/cea884d68397ac69/biorestorative-therapies-reports-strong-financial-growth-and-clinical-advancements-in-2024 2025-03-28T02:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/3245d60341d0bfc7/humacyte-advances-bioengineered-vessel-technology-following-fda-approval-for-vascular-trauma 2025-03-28T02:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/7ffe0da954141ba5/evolving-paradigm-addressing-women-s-underrepresentation-in-clinical-trials 2025-03-28T02:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/9fd88e879c56a952/actinium-pharmaceuticals-unveils-atnm-400-a-breakthrough-non-psma-targeted-radiotherapy-for-prostate-cancer 2025-03-28T02:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/a9790b0a3705c48a/port-7-shows-over-90-tumor-reduction-in-mesothelioma-preclinical-studies-first-in-human-trial-planned 2025-03-28T01:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/16e0d84c15cece8a/neurogene-halts-high-dose-arm-of-rett-syndrome-gene-therapy-trial-following-serious-adverse-event 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7bf4fb636e608428/sglt2-inhibitors-show-promise-as-novel-immunomodulatory-therapy-for-autoimmune-diseases 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2696e3cdb3d9268/shanton-s-sap-001-shows-breakthrough-results-in-refractory-gout-phase-2b-trial 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc6e159d6731f3be/sensei-biotherapeutics-reports-promising-results-for-vista-targeting-antibody-in-pd-l1-resistant-tumors 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1e8768224cc03bc5/medication-nonadherence-drives-125-billion-in-avoidable-healthcare-costs-and-200000-deaths-annually-in-europe 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebc7f9800abfb512/curium-expands-european-nuclear-medicine-footprint-with-strategic-acquisitions-of-nucleis-and-monrol 2025-03-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6bc51958cda66a59/nirogacestat-shows-deepening-long-term-responses-in-desmoid-tumor-patients 2025-03-27T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/d79c9be4b267aa35/cleerly-to-present-groundbreaking-ai-study-on-cardiovascular-risk-in-women-at-acc-25 2025-03-27T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/2e11e27cfcedf072/lantern-pharma-reports-strong-clinical-results-and-ai-platform-advancements-in-2024-year-end-update 2025-03-27T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/af7a7ee105f594a2/health-canada-expands-hyqvia-authorization-for-cidp-maintenance-therapy 2025-03-27T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/9ed14ad42000896d/urteste-to-launch-european-clinical-trials-for-novel-pancreatic-cancer-urine-test-in-q3-2025 2025-03-27T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/834d26851c107a4c/remote-patient-monitoring-revolution-how-covid-19-transformed-healthcare-delivery 2025-03-27T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/e70d14f2e247115e/spyglass-pharma-appoints-veteran-pharmaceutical-executive-as-chief-r-d-officer-to-advance-intraocular-drug-delivery-platform 2025-03-27T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/760c2e3adb556921/sirna-therapeutics-surge-over-150-industry-sponsored-clinical-trials-conducted-in-recent-years 2025-03-27T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/3c6c3f32a6c90541/novel-immunotherapy-ost-her2-shows-promise-for-osteosarcoma-treatment-featured-in-pbs-documentary 2025-03-27T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/c89930907e8a00a3/scinai-to-acquire-pincell-advancing-novel-antibody-treatment-for-severe-skin-disorders 2025-03-27T16:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/68a0a5e96c93bb74/merck-s-subcutaneous-pembrolizumab-shows-comparable-efficacy-to-iv-keytruda-with-significantly-reduced-administration-time 2025-03-27T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/618d860f4e55c83c/china-proposes-up-to-6-years-of-clinical-trial-data-exclusivity-in-draft-measures 2025-03-27T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/183bf93e6e60250b/innovative-trial-designs-emerge-after-immunotherapy-setbacks-in-head-and-neck-cancer 2025-03-27T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/57b6905ea54edbde/lupus-foundation-of-america-launches-lfa-lift-to-streamline-clinical-trials-and-accelerate-treatment-development 2025-03-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/bbc758e73217cc66/curevac-wins-key-patent-validity-decision-in-ongoing-mrna-litigation-against-biontech 2025-03-27T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5511be7e108e71c/aeon-biopharma-appoints-rob-bancroft-as-new-ceo-to-lead-abp-450-therapeutic-development 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ea1954a9dfed0d4/spyre-therapeutics-initiates-phase-1-trial-of-novel-long-acting-il-23-antibody-for-ibd-treatment 2025-03-27T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5d20d46d81c22d3/ekf-diagnostics-appoints-gavin-jones-as-ceo-to-drive-point-of-care-growth-strategy 2025-03-27T15:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/3be2d4330f263685/bausch-lomb-recalls-envista-intraocular-lenses-due-to-inflammatory-complications 2025-03-27T15:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/7de59df588ca017f/invivoscribe-s-leukostrat-cdx-flt3-mutation-assay-receives-regulatory-approval-in-uk-and-switzerland 2025-03-27T14:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/7f857e0a44592b0b/beyondspring-s-plinabulin-shows-promising-survival-benefits-in-lung-cancer-and-strategic-advances-in-protein-degradation 2025-03-27T13:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/faa70dd7d94a2a93/yoda-therapeutics-initiates-phase-2-trial-of-ya-101-for-multiple-system-atrophy 2025-03-27T13:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/1682a299e991142e/galatea-bio-secures-25m-to-build-global-biobank-focused-on-diverse-genetic-data 2025-03-27T13:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/a734b658b6e8adf6/alvotech-s-xolair-biosimilar-avt23-achieves-positive-phase-iii-results-and-uk-regulatory-acceptance 2025-03-27T13:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/a31b5fa98870b8de/drone-technology-trials-begin-for-rapid-delivery-of-radioactive-medicines-in-coventry 2025-03-27T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/c0b9856ba8ec4565/neonc-technologies-partners-with-cbcc-global-research-to-accelerate-brain-cancer-clinical-trials-in-india 2025-03-27T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/fcb8760696a0bf01/cnd-life-sciences-to-present-breakthrough-skin-biopsy-data-for-dementia-diagnosis-at-aan-2025 2025-03-27T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/0cf38156c5bc998f/alzinova-s-alz-101-vaccine-advances-to-phase-2-trial-following-successful-drug-substance-production 2025-03-27T09:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/b45b9d358e7e859b/phase-2-precision-study-launches-3-fraction-sbrt-protocol-for-prostate-cancer-treatment 2025-03-27T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/a08288b4bee79230/intelligent-bio-solutions-expands-global-reach-with-strategic-partnership-in-spain-and-andorra 2025-03-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b68c0a11448a3d5a/health-canada-authorizes-4moving-biotech-s-phase-2a-trial-for-novel-knee-osteoarthritis-treatment 2025-03-27T08:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/5a602141a6776fec/jaguar-health-s-crofelemer-shows-promising-results-for-breast-cancer-patients-with-treatment-related-diarrhea 2025-03-27T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8ffba29da414288/polyrizon-advances-pl-14-allergy-blocker-with-successful-safety-study-and-clinical-strategy 2025-03-27T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f8701d88f77a29e/glyconex-to-present-novel-glycan-targeting-adc-data-for-gastric-cancer-at-aacr-2025 2025-03-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa271af347f396bf/fda-approves-tablet-formulation-of-livmarli-for-rare-pediatric-liver-diseases 2025-03-27T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea27d3e576106e83/tecentriq-and-avastin-combination-now-funded-for-advanced-liver-cancer-in-new-zealand 2025-03-27T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/9a5d4eb7a5adc729/northstrive-biosciences-expands-licensing-agreement-to-target-animal-health-market 2025-03-27T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d5123ed7b4de6b8/robust-pipeline-of-80-therapies-advancing-for-chronic-kidney-disease-treatment-in-2025 2025-03-27T04:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/8e94d0746339d7b2/drug-shortages-crisis-causes-impacts-and-solutions-in-the-us-healthcare-system 2025-03-27T04:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/f9f82b9be1f8a833/kalvista-completes-enrollment-in-pediatric-hae-trial-for-oral-therapy-sebetralstat 2025-03-27T02:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/e90e5f66fc31046e/ryvu-therapeutics-advances-synthetic-lethality-pipeline-with-promising-preclinical-data-at-aacr-2025 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/2cd1c8e666115ad0/dyadic-international-reports-strong-2024-performance-with-1-9-million-in-milestone-and-license-revenue 2025-03-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed4cddc6e0f45e14/alcon-acquires-majority-stake-in-aurion-biotech-to-advance-first-ever-corneal-cell-therapy 2025-03-26T23:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/f0721c3e0374c4ac/bayer-secures-global-license-for-novel-prmt5-inhibitor-targeting-mtap-deleted-tumors 2025-03-26T23:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/b399b311d4116e3e/first-patient-dosed-in-phase-ii-jaspis-01-trial-of-dapolsertib-for-relapsed-refractory-dlbcl 2025-03-26T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/387838c602f2dd95/chosa-s-platinum-drug-response-predictor-shows-promise-in-personalizing-cancer-treatment 2025-03-26T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/f87642af0f5634e0/rani-therapeutics-achieves-bioequivalence-with-oral-glp-1-glp-2-dual-agonist-for-obesity-treatment 2025-03-26T22:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/21a82be7f584addc/fda-approves-first-treatment-for-insatiable-hunger-in-prader-willi-syndrome 2025-03-26T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/84ca99431c2dc4a1/fda-approves-first-treatment-for-hyperphagia-in-prader-willi-syndrome 2025-03-26T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/8dde8f32a17b01a7/medrio-unveils-enhanced-rtsm-solution-to-accelerate-clinical-trial-implementation 2025-03-26T22:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/933f83d3033b1c06/microplastics-exposure-linked-to-higher-rates-of-cardiovascular-disease-and-diabetes-in-coastal-communities 2025-03-26T20:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/699788460c50e3e1/ose-immunotherapeutics-reports-strong-financial-results-and-pipeline-progress-in-2024 2025-03-26T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/11ae41cfb00e251f/vaximm-s-vxm01-avelumab-combination-shows-promise-in-phase-2a-glioblastoma-trial 2025-03-26T19:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/e90ba10ff09dae1d/nitisinone-shows-promise-as-novel-malaria-control-strategy-by-making-human-blood-lethal-to-mosquitoes 2025-03-26T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/0599a90b86db5f7e/uveitis-and-optic-neuritis-markets-set-for-major-growth-through-2034-as-new-therapies-advance 2025-03-26T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/dcc3c2b43bdf59aa/anhorn-medicines-initiates-phase-i-trial-of-novel-protein-degrader-for-hair-loss 2025-03-26T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/b4c4e7f3a3d91fc3/nanoscope-s-optogenetic-gene-therapy-shows-promise-in-retinitis-pigmentosa-clinical-trials 2025-03-26T19:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/b073ea79e80de9b0/kura-oncology-s-ko-2806-shows-promise-in-combination-therapy-for-renal-cell-carcinoma 2025-03-26T17:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/2a163591d69f955a/federal-circuit-rules-generic-drugmakers-can-deduct-hatch-waxman-litigation-expenses 2025-03-26T17:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/981a4a08e847e4d3/nuvectis-pharma-to-present-promising-nxp900-data-at-2025-aacr-meeting 2025-03-26T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/4c11f00f4283d7e3/epicrispr-biotechnologies-secures-68-million-to-advance-first-epigenetic-therapy-for-fshd 2025-03-26T16:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/f7304895d6b23554/ideaya-s-wrn-inhibitor-ide275-shows-promise-for-msi-h-cancers-featured-in-aacr-2025-oral-presentation 2025-03-26T16:38:54+00:00 hourly 0.9 https://trial.medpath.com/news/ae490edf3278cd5b/briacell-to-present-pivotal-breast-cancer-immunotherapy-data-at-aacr-2025 2025-03-26T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/news/d465aeb93bc1b4ba/over-220-pipeline-therapies-in-development-for-non-hodgkin-s-lymphoma-reports-delveinsight 2025-03-26T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/f19cbccc5514103a/ema-evaluating-fast-track-status-for-intrathecal-zolgensma-in-spinal-muscular-atrophy 2025-03-26T16:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/026a4dcc968a3ea4/delhi-high-court-halts-natco-pharma-s-generic-risdiplam-launch-in-roche-patent-dispute 2025-03-26T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/aef2c690aff40138/wave-life-sciences-to-seek-fda-approval-for-duchenne-muscular-dystrophy-drug-following-promising-phase-2-results 2025-03-26T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/ec479270a633c6db/medicenna-to-present-mdna11-ability-1-trial-update-and-novel-mdna113-data-at-aacr-2025 2025-03-26T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/418d5120b685905f/lutris-pharma-to-present-phase-2-results-of-novel-b-raf-inhibitor-for-egfr-inhibitor-induced-skin-rash-at-aacr-2025 2025-03-26T16:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/02b7e89d1d54af7a/igc-pharma-reports-78-reduction-in-sleep-disturbances-with-igc-ad1-in-alzheimer-s-phase-2-trial 2025-03-26T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/d8b94c81511f60a5/diaceutics-secures-ps11-5m-contract-with-partner-therapeutics-to-commercialize-oncology-precision-medicine-bizengri 2025-03-26T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/d0d7d503be9739d9/cytosite-bio-partners-with-lantheus-to-develop-granzyme-b-pet-imaging-for-real-time-immunotherapy-monitoring 2025-03-26T16:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/dda03ac63da96bf7/covid-19-inflammatory-response-varies-significantly-across-pandemic-waves-study-of-8614-patients-reveals 2025-03-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bc50c5bf41bc8a3/avalo-therapeutics-advances-il-1b-antibody-in-phase-2-trial-for-hidradenitis-suppurativa-with-promising-market-potential 2025-03-26T13:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/b517006014eaf421/abbvie-to-present-novel-cancer-therapies-abbv-969-and-abbv-514-at-aacr-annual-meeting-2025 2025-03-26T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/b9452c476fac673c/knight-therapeutics-launches-minjuvi-for-relapsed-refractory-dlbcl-in-mexico 2025-03-26T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/e56b04d36dc24e08/fda-issues-approvable-letter-for-nyxoah-s-genio-system-for-obstructive-sleep-apnea 2025-03-26T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/4f7576dbc9d00e4b/merck-s-winrevair-shows-promising-phase-3-results-for-pulmonary-arterial-hypertension-treatment 2025-03-26T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/1e74680b6d8a2265/heidelberg-pharma-to-showcase-novel-adc-technologies-targeting-gastrointestinal-cancers-at-aacr-2025 2025-03-26T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/9e00f3e716d9d720/applied-dna-sciences-seeks-nysdoh-approval-for-novel-h5-bird-flu-diagnostic-test 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c68426fb7c4653dc/cypath-r-lung-demonstrates-clinical-impact-in-real-world-lung-cancer-detection-cases 2025-03-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebb288192b91cb9c/genflow-biosciences-secures-ps434083-investment-to-launch-gene-therapy-trial-in-aged-dogs 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/360729d39b0eebc2/supira-medical-raises-120m-in-series-e-funding-completes-support-i-enrollment-for-novel-cardiac-support-device 2025-03-26T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa6cab174cd0e5eb/quantum-si-launches-platinum-pro-protein-sequencer-to-advance-drug-development-and-proteomics-research 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc36ea089fa74f30/gv20-therapeutics-partners-with-mitsubishi-tanabe-to-develop-novel-ai-discovered-antibody-drug-conjugates 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b87f9331225e4d0f/aligos-therapeutics-reports-promising-96-week-data-for-hbv-treatment-and-positive-results-in-mash-study-at-apasl-2025 2025-03-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb9f612fe74c8172/fda-grants-fast-track-designation-to-sanofi-s-mrna-chlamydia-vaccine-candidate 2025-03-26T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/cfec7e83e8d4f66c/israel-unveils-streamlined-drug-approval-process-to-accelerate-patient-access 2025-03-26T07:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/33526b8323a2f00d/hydroxychloroquine-shows-promise-as-pretreatment-for-til-cancer-therapy-juncell-therapeutics-reports 2025-03-26T06:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed1fcd4580ff5447/penn-researchers-develop-safe-dna-delivery-system-using-lipid-nanoparticles-for-chronic-disease-treatment 2025-03-26T04:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/de9706789ca25c29/fda-provides-positive-feedback-on-pleco-s-ptx-252-for-acute-myeloid-leukemia-treatment 2025-03-26T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f2b2fa33ebb10a0/alarming-rise-in-heart-related-maternal-deaths-in-the-us-study-finds 2025-03-26T02:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/8948bd2e081b5423/pharmacy-deserts-and-biosimilar-adoption-reshape-managed-care-landscape 2025-03-26T02:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/804ba3061804d0ac/novo-nordisk-invests-2-billion-in-chinese-triple-g-weight-loss-treatment 2025-03-26T01:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/135580f26af95a95/ascentage-pharma-unveils-promising-preclinical-data-for-five-oncology-drug-candidates-at-aacr-2025 2025-03-26T01:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/186c3fe7289b515d/city-of-hope-launches-dinomite-trial-testing-papaverine-to-enhance-radiation-therapy-in-rectal-cancer 2025-03-26T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/04689d6fd9ad31ba/divitum-r-tka-blood-test-shows-promise-in-predicting-immunotherapy-response-across-multiple-cancers 2025-03-26T00:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/25ed0ce9ceed1792/bcg-revaccination-fails-to-prevent-tuberculosis-infection-in-large-phase-2b-trial 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff1f897e60206fcd/gene-solutions-spot-mas-becomes-asia-s-first-clinically-validated-multi-cancer-blood-test 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd4c8b79fdb22b23/robust-pipeline-of-200-therapies-targets-colorectal-cancer-treatment-landscape 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6acf1748e0f2ee0/amgen-develops-pan-kras-inhibitor-amg-410-to-target-broader-range-of-kras-mutant-tumors 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/20eb49587fe160ea/hong-kong-achieves-first-myeloma-car-t-treatment-using-mainland-manufactured-therapy 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f84f776a3f783f37/mabwell-to-showcase-six-novel-cancer-therapeutics-at-2025-aacr-annual-meeting 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c90004a0606cb0b2/lunit-and-astrazeneca-to-present-ai-model-for-egfr-mutation-prediction-in-nsclc-at-aacr-2025 2025-03-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed2173525de1f466/nouscom-s-nous-209-shows-promising-results-in-cancer-interception-for-lynch-syndrome-patients 2025-03-25T22:35:47+00:00 hourly 0.9 https://trial.medpath.com/news/67110dd33d6925c5/aulos-bioscience-to-present-promising-phase-2-data-for-novel-il-2-therapeutic-in-melanoma-treatment 2025-03-25T22:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/4168ef4ea542b78b/belay-diagnostics-and-genomoncology-partner-to-enhance-cns-cancer-liquid-biopsy-testing 2025-03-25T22:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/02ab52be4b890e9e/fda-approves-blujepa-first-novel-oral-antibiotic-for-utis-in-over-two-decades 2025-03-25T22:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/8970b1bbc9c1b28a/fda-approves-egrifta-wrtm-new-weekly-reconstitution-formulation-for-hiv-associated-lipodystrophy 2025-03-25T22:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/ebc13a80c9a10f4f/relmada-therapeutics-secures-licensing-for-novel-bladder-cancer-treatment-ndv-01 2025-03-25T20:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/1b15d1afc2673c06/pricing-dynamics-of-rare-disease-drugs-how-prevalence-and-patient-numbers-shape-market-access 2025-03-25T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/7340c3706493c2d3/axsome-s-sunosi-shows-positive-phase-3-results-in-adult-adhd-trial 2025-03-25T20:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/6a713e79675daed8/gsk-s-oral-carbapenem-antibiotic-tebipenem-hbr-succeeds-in-phase-3-trial-setting-stage-for-fda-filing 2025-03-25T20:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/381011c85ab5c12c/dexcom-advances-diabetes-management-with-15-day-cgm-sensor-and-expanded-type-2-applications 2025-03-25T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/ea5caa087262c205/intelligent-bio-solutions-fingerprint-drug-screening-system-on-track-for-2025-fda-clearance 2025-03-25T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/6620fbc218f41a14/fda-approves-blujepa-first-new-class-of-oral-antibiotic-for-utis-in-nearly-30-years 2025-03-25T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/b7a228774fee577e/linus-health-to-showcase-digital-cognitive-assessment-tools-at-ad-pd-2025-conference 2025-03-25T18:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/8b80a664cf7acc2b/character-biosciences-secures-93m-to-advance-precision-therapies-for-age-related-macular-degeneration 2025-03-25T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/7947e58e9d89a1a1/schrodinger-unveils-promising-preclinical-data-for-novel-cancer-therapeutics-at-aacr-2025 2025-03-25T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/cee0ededee0f2833/imcheck-s-ict01-shows-unprecedented-complete-remission-rates-in-aml-combination-therapy 2025-03-25T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/7bafbca372ed7509/early-combination-of-statins-and-ezetimibe-could-prevent-thousands-of-heart-attacks-study-finds 2025-03-25T16:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/c4b2bf9775d899d2/surrozen-abandons-hepatitis-drug-development-following-phase-i-failure-shifts-focus-to-ophthalmology 2025-03-25T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/8b4f21d6b2a58328/health-canada-approves-arjuna-s-shoden-r-ashwagandha-extract-as-natural-health-product 2025-03-25T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/7c24f6eeb0fa16c6/fda-accepts-scholar-rock-s-bla-for-apitegromab-in-spinal-muscular-atrophy-with-priority-review 2025-03-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/ad713ed73600a524/nasa-awards-redwire-contract-for-advanced-pharmaceutical-research-on-international-space-station 2025-03-25T16:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/e0c50825d090b855/merck-licenses-oral-lipoprotein-a-inhibitor-hrs-5346-from-hengrui-pharma-in-1-97-billion-deal 2025-03-25T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/075f73374d136faa/splash-clinical-and-c2n-diagnostics-partner-to-revolutionize-alzheimer-s-trial-recruitment-with-blood-based-biomarkers 2025-03-25T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/4fcdf9e3a5aee5fb/veracyte-s-whole-genome-sequencing-mrd-test-shows-superior-accuracy-for-bladder-cancer-detection 2025-03-25T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/82d740b6b91e8bd4/anixa-biosciences-partners-with-verdi-solutions-to-develop-ai-guided-cancer-vaccines 2025-03-25T15:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/3cc25223912d800c/fda-grants-qidp-designation-to-vast-therapeutics-alx1-for-pseudomonas-infections-in-bronchiectasis 2025-03-25T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a138f10fc9b1a78/cantargia-s-novel-anti-il1rap-antibody-drug-conjugate-shows-promising-preclinical-efficacy-against-cancer 2025-03-25T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/913a33d30f335dc0/fda-signals-potential-traditional-approval-pathway-for-genelux-s-olvi-vec-in-platinum-resistant-ovarian-cancer 2025-03-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/27aeb2edc5dde94e/bayer-to-present-comprehensive-kerendia-clinical-data-at-major-cardiology-and-nephrology-conferences 2025-03-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/6da11628e39f0e2e/enable-injections-secures-ce-mark-approval-for-enfuse-wearable-drug-delivery-platform-in-europe 2025-03-25T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/9472a7cdc8f4df5f/accent-therapeutics-to-showcase-novel-cancer-therapeutics-atx-559-and-atx-295-at-aacr-2025 2025-03-25T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d3b51315a3667ec/berubicin-for-glioblastoma-cns-pharmaceuticals-reports-comparable-efficacy-to-standard-treatment-with-improved-safety-profile 2025-03-25T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f15b3d30c90a644/hubble-therapeutics-secures-7-3m-series-a-funding-for-gene-therapy-targeting-rare-childhood-blindness 2025-03-25T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/edc01d2df1b87728/chemoid-assay-significantly-improves-response-rates-in-platinum-resistant-ovarian-cancer 2025-03-25T10:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/cd414ace631e38b8/biontech-moderna-lead-the-race-in-personalized-cancer-vaccine-development-with-promising-clinical-results 2025-03-25T10:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/18eea52ad08338ce/edaravone-shows-promise-in-targeting-tdp-43-mislocalization-in-als-new-preclinical-research-reveals 2025-03-25T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b8f45cc09a683e7/kyan-technologies-optim-ai-platform-demonstrates-85-clinical-concordance-across-multiple-cancer-types 2025-03-25T08:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/02d0818cb0935ed3/flerie-and-toleranzia-announce-merger-plan-to-take-toleranzia-private-in-eur12-5-million-deal 2025-03-25T08:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcfc17c1b39fb39e/needle-free-drug-delivery-devices-market-set-to-reach-5-billion-by-2035 2025-03-25T07:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/2db1beccbe1fa42a/hillstar-bio-raises-67m-series-a-to-advance-precision-immunotherapy-for-autoimmune-diseases 2025-03-25T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6dae204431b4239/nervgen-pharma-to-present-phase-1b-2a-trial-of-nvg-291-for-spinal-cord-injury-at-upcoming-investor-event 2025-03-25T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/88bc8f945d355678/charles-river-and-valo-health-achieve-first-ai-driven-lupus-drug-candidate-using-logica-platform 2025-03-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c66a18e1dbf650be/mr-linac-technology-advances-precision-radiation-therapy-across-multiple-cancer-types 2025-03-25T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/71d1edc4091e1086/nutrition-s-critical-role-in-cancer-care-from-prevention-to-survivorship 2025-03-25T03:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/a0bab4767f5036fe/ai-tool-successfully-predicts-prostate-cancer-treatment-outcomes-by-measuring-tumor-volume 2025-03-25T03:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/e5807356da3f23da/solve-fshd-partners-with-modalis-to-develop-crispr-based-epigenome-editing-therapy-for-muscular-dystrophy 2025-03-25T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7845ca9d3494920/lipoprotein-a-the-overlooked-cardiovascular-risk-factor-gaining-clinical-recognition 2025-03-25T02:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/fdc4c299e4898779/neurosafe-technique-shows-significant-improvement-in-erectile-function-after-prostate-cancer-surgery 2025-03-25T02:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/0c3f2a1cc49d9afd/iovance-biotherapeutics-continues-expansion-with-nearly-300-new-stock-option-grants-to-support-til-therapy-development 2025-03-25T02:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/b3631c6fa2a42935/urolift-system-demonstrates-superior-patient-outcomes-in-head-to-head-bph-treatment-trials 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6eae6dd46fa32fa2/oncotelic-therapeutics-completes-phase-1-trial-of-ot-101-il-2-combination-for-advanced-solid-tumors 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b4faced36d458cd/china-nmpa-clears-phase-2-trial-of-first-in-class-sialidase-enzyme-therapy-for-autoimmune-kidney-disease 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/088827c2547cbc4e/fda-approval-of-humacyte-s-artificial-blood-vessel-faces-petition-for-revocation-amid-safety-concerns 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c20c89082e43eeb1/early-rituximab-treatment-shows-significant-benefits-for-advanced-stage-low-tumor-burden-follicular-lymphoma 2025-03-24T22:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/ac8a49fe1107f57b/fda-expands-tenon-medical-s-catamaran-system-indication-for-thoracolumbar-fusion-augmentation 2025-03-24T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/30c0a2eb4de1f3c8/opm-101-enters-phase-1b-2a-trial-to-combat-melanoma-resistance-to-immunotherapy 2025-03-24T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/4af94b986586c77a/anuncia-medical-s-reflow-evd-receives-fda-breakthrough-device-designation-for-intracranial-pressure-management 2025-03-24T19:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/bc263139976a95d7/fda-grants-510-k-clearance-to-dawes-redman-ctg-analysis-for-fetal-monitoring-in-the-us 2025-03-24T19:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/9a8d53e78d28c6ab/fda-approves-abbott-s-coronary-ivl-system-trial-for-treating-calcified-coronary-artery-disease 2025-03-24T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/e114cfbfed3e891a/experts-challenge-conventional-wisdom-on-drug-launch-pricing-evaluations 2025-03-24T19:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/d11ecb49b96c3de4/opthia-faces-1-billion-investor-obligation-following-sozinibercept-trial-failure-in-wetamd 2025-03-24T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/eb34e8891115df3e/spark-biomedical-completes-enrollment-in-two-pivotal-neurostimulation-trials-for-opioid-use-disorder-and-neonatal-withdrawal 2025-03-24T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/853842dae5a71980/closed-loop-medicine-secures-us-patents-for-ai-powered-precision-dosing-in-glp-1-and-doac-therapies 2025-03-24T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/d3160b7a304f136a/miebo-shows-rapid-relief-for-dry-eye-disease-within-minutes-of-first-use-phase-4-study-reveals 2025-03-24T16:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/5ae21956e1847d79/fda-aligns-with-enabled-therapeutics-on-cpt-021-novel-targeted-therapy-for-alzheimer-s-disease 2025-03-24T16:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/fd33d07816a01bae/fda-grants-fast-track-designation-to-sungen-biomedical-s-novel-antibody-for-acute-myocardial-infarction 2025-03-24T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/478e09a96184023c/agilent-s-xcelligence-technology-plays-critical-role-in-fda-approval-of-autolus-car-t-therapy 2025-03-24T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/88bb8838969a2a70/secretome-therapeutics-initiates-phase-1-trial-of-novel-cell-therapy-stm-01-for-heart-failure 2025-03-24T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/0a2dcc411cb61c0d/privo-technologies-launches-benevet-oncology-to-bring-human-cancer-treatment-innovations-to-veterinary-medicine 2025-03-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/cb24801cb31b8032/tempero-bio-secures-70m-series-b-to-advance-novel-addiction-treatment-through-phase-2-trials 2025-03-24T16:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/adbc09f98374359a/aquablation-therapy-shows-comparable-efficacy-to-laser-enucleation-with-better-sexual-function-preservation-in-bph-treatment 2025-03-24T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/4b97805915d72267/phasev-unveils-ai-powered-platform-to-revolutionize-clinical-trial-design-and-analysis 2025-03-24T16:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/d1ef86a1e55b1fa3/hoth-therapeutics-to-pursue-expanded-access-for-ht-001-to-treat-egfr-inhibitor-related-skin-toxicities 2025-03-24T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea636f0b4bedffe0/can-fite-launches-fda-ema-approved-phase-3-trial-for-oral-psoriasis-drug-piclidenoson 2025-03-24T13:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/af9676ce197eed80/mit-develops-revolutionary-injectable-drug-depot-system-for-long-term-medication-delivery 2025-03-24T13:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/bf23083efcb3c61f/powerful-medical-s-ai-driven-ecg-model-for-stemi-detection-receives-fda-breakthrough-designation 2025-03-24T13:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/279f0bfc37cb7129/mira-pharmaceuticals-to-acquire-skny-pharmaceuticals-expanding-into-200-billion-weight-loss-and-smoking-cessation-markets 2025-03-24T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/a5bdd2a4a41552b6/augustine-therapeutics-secures-eur78-million-to-advance-hdac6-inhibitor-for-charcot-marie-tooth-disease 2025-03-24T10:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/5e2507cf0b1bb5b7/biophytis-reports-promising-results-bio101-and-glp-1-combination-restores-muscle-strength-in-obesity 2025-03-24T10:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/9fbe412961d073fa/cizzle-biotechnology-expands-global-reach-for-early-lung-cancer-detection-test 2025-03-24T10:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/bff5faa304b068ec/novel-iron-based-nanoparticles-could-revolutionize-triple-negative-breast-cancer-treatment 2025-03-24T10:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/b8dae37746f8c212/biocon-pharma-secures-fda-approval-for-norepinephrine-bitartrate-injection-for-acute-hypotension 2025-03-24T10:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/c2c7372a82082e80/hong-kong-streamlines-drug-registration-process-with-new-consultation-services 2025-03-24T10:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/3f9abe6f67945938/crispr-cas9-market-set-to-surge-over-25-therapies-in-clinical-trials-expected-to-launch-within-5-7-years 2025-03-24T10:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/44f0faa6d52071e5/gilead-sciences-launches-groundbreaking-hiv-cure-trial-in-south-africa-focusing-on-women 2025-03-24T10:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/282ad02426733a69/tharimmune-reports-breakthrough-in-oral-delivery-of-tnf-a-inhibitor-for-inflammatory-diseases 2025-03-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a98b70fb0889e3c/arkbio-s-ak0901-completes-phase-iii-trial-for-adhd-in-china-showing-significant-efficacy 2025-03-24T04:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/e3483de6e4725d62/transcode-therapeutics-secures-10-million-funding-to-advance-rna-cancer-therapy-clinical-trials 2025-03-24T04:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/9c74f1fb52405732/clover-advances-rsv-vaccine-program-with-fda-clearance-for-revaccination-trial 2025-03-24T04:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/82409cadccc5d1c7/glp-1-receptor-agonists-vs-sglt2-inhibitors-comparative-cardiovascular-benefits-in-diabetes-management 2025-03-24T03:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/0ec741844386f77e/nih-researchers-develop-eye-drops-that-could-slow-progression-of-retinitis-pigmentosa 2025-03-24T01:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/3ade140eac837637/fda-clears-everest-medicines-ind-application-for-novel-mrna-cancer-vaccine-evm14 2025-03-24T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/a251444db9cd45e6/innovent-begins-phase-3-trial-of-novel-her2-adc-for-platinum-resistant-ovarian-cancer 2025-03-24T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/d14e2ff3d81957fc/coherus-reports-promising-phase-1-data-for-chs-114-in-head-and-neck-cancer-showing-potential-to-overcome-pd-1-resistance 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8829231fc4bdc6a/who-prequalifies-first-maternal-rsv-vaccine-and-issues-global-immunization-recommendations 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb7835a75db1b645/novel-tim-3-decoy-enhances-car-t-cell-therapy-efficacy-in-b-cell-acute-lymphoblastic-leukemia 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ac205d6fd0ebef2/pipeline-advances-in-head-and-neck-cancer-treatment-over-100-drugs-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/02ffe6c8f88bb917/b-cell-lymphoma-pipeline-expands-with-300-therapies-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ce90b265e985220/carbogen-amcis-achieves-gmp-certification-for-french-sterile-drug-manufacturing-facility 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a20a871e6471837/cdsco-panel-rejects-phase-iii-trial-waivers-for-resmetirom-in-india-approves-bioequivalence-studies 2025-03-23T22:38:02+00:00 hourly 0.9